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ABSTRACT
Toxoplasmosis is a disease caused by a single-celled protozoan parasite known as 
Toxoplasma gondii. It infects approximately one-third of the world’s population. The 
definitive hosts of this obligate intercellular parasite are feline family members; but it is 
widespread in human and many warm-blooded animals, particularly farm animals. The 
disease causes critical symptoms in infants, pregnant women, and fetuses and there is 
still an urgent need new more effective therapeutic, diagnostic and bioimaging 
compounds as well as affordable production methods amenable to upscaling. A plant-
based recombinant antibody against Toxoplasma antigen may offer a potential approach 
in developing strategies to produce such molecules. The antibody was designed to 
specifically target surface protein of the T.godii tachyzoites can be further developed as 
targeting antibodies or diagnostic reagents against the organism. Thus, in this study, 
anti-Toxoplasma scFv antibody genes were introduced into the pCambia1304 vector 
and transformed into Musa acuminata cv. Berangan and Nicotiana tabacum L. cv. SR1 
leaf discs through Agrobacterium-mediated transformation. In addition, a KDEL 
retention sequence and Bowman-birk Serine proteinase inhibitor genes were added into 
the construct to stabilize and enhance the scFv antibody production. The transgene was 
successfully integrated into the tobacco genome. Unfortunately, the desired gene failed 
to integrate into banana genome despite many attempts and the possible constrains are 
discussed. Molecular analysis including PCR and Real-time PCR were used to confirm 
the integration of transgene into the plant genome. From Real-time PCR results, the 
average mRNA level for the leaves transformed with the construct pToxo130BBI based 
on the RT-qPCR of three transgenes elements was 4.4 fold when compared to non-
transformed tobacco whereas for the construct pToxo130BBIKDEL, it was 3.58 fold 
higher. The unexpected lower level of mRNA for pToxo130BBIKDEL compared to 
III
pToxo130BBI (0.82 fold) in Real-time PCR may not reflect the actual protein 
accumulation level in plant cell. Further studies need to be carried out to examine the 
effectiveness of adding KDEL retention sequence and Bowman-birk Serine proteinase 
inhibitor genes in the constructs through quantitative analysis of the tobacco-expressed 
protein. Overall, the study proposes a potentially useful expression platform for 
production of anti-Toxoplasma scFv antibodies.
IV
ABSTRAK
Toxoplasmosis adalah penyakit yang disebabkan oleh parasit protozoa yang bersel 
tunggal, iaitu Toxoplasma gondii. Ia menjangkiti kira-kira satu pertiga daripada 
populasi dunia. Perumah definitif untuk parasit ini adalah ahli keluarga kucing tetapi ia 
telah berleluasa di kalangan manusia dan haiwan yang berdarah panas, terutamanya 
haiwan ternakan. Penyakit ini menyebabkan gejala-gejala kritikal dalam bayi, wanita 
yang berhamil, dan janin. Oleh itu, therapeutik yang berkesan, diagnostik dan 
“bioimaging compound”serta kaedah penghasilan yang berpatutan dan berskala besar  
adalah diperlukan  segera. Antibodi rekombinan terhadap antigen Toxoplasma yang 
berasaskan tumbuhan berkemungkinan besar boleh menawarkan satu pendekatan yang 
berpotensi dalam membangunkan strategi untuk menghasilkan molekul tersebut. 
Antibodi yang direka khususnya untuk menentang protein di permukaan tachyzoites 
T.gondii boleh diubahsuaikan sebagai antibodi atau reagen diagnostik yang menentang 
organisma tersebut. Oleh itu, dalam kajian ini, gen antibodi scFv terhadap antigen 
Toxoplasma telah diperkenalkan ke dalam vektor pCambia 1304 dan ditransformasi ke 
dalam Musa acuminata cv. Berangan dan daun Nicotiana tabacum L. cv. SR1 dengan 
menggunakan Agrobacterium. Di samping itu, “KDEL retention sequence” dan 
“Bowman-birk Serine proteinase inhibitor gene” telah ditambah ke dalam konstruk 
untuk menstabilkan dan meningkatkan penghasilan antibodi scFv. Transgen tersebut 
telah berjaya diintegrasikan ke dalam genom tembakau, tetapi, gagal untuk 
diintegrasikan ke dalam genom pisang selepas beberapa kali pencubaan. Analisis 
molekul seperti PCR dan Real-time PCR telah digunakan untuk mengesahkan integrasi 
transgen ke dalam genom tumbuhan. Berdasarkan keputusan Real-time PCR, tahap 
purata mRNA bagi tembakau yang ditransformasi dengan pToxo130BBI konstruk 
adalah 4.4 kali ganda berbanding tembakau yang tidak-ditransformasi; manakala bagi 
VpToxo130BBIKDEL konstruk, ia hanya 3.58 kali ganda lebih tinggi. Tahap mRNA 
adalah di luar jangkaan iaitu, pToxo130-BBI-KDEL lebih rendah berbanding 
pToxo130BBI (0.82 kali ganda).Walau bagaimanapun, keputusan Real-time PCR tidak 
mewakili tahap penghasilan protein yang sebenar di dalam sel tumbuhan. Kajian yang 
selanjutnya perlu dijalankan untuk mengkaji keberkesanan penambahan “KDEL 
retention sequence” dan “Bowman-birk Serine proteinase inhibitor gene” dalam 
konstruk melalui analisis kuantitatif terhadap tembakau-ekspres protein. Secara 
keseluruhannya, kajian ini mencadangkan platform yang berpotensi untuk menghasilkan 
antibodi scFv terhadap Toxoplasma.
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1CHAPTER 1:INTRODUCTION
1.1 General introduction
Toxoplasmosis gondii is an obligate intracellular parasite that is estimated to 
infect approximately one-third of the world’s population. This one-celled parasite was 
first discovered by Nicolle and Manceaux in 1908 and named a year later (Dubey, 2008). 
It is classified under the phylum of Apicomplexa, subclass Coccidia.
The parasites are reproduced in 2 different ways, through sexual and asexual 
cycles. The sexual cycle occurs in the gut of the cat family both wild and domesticated 
as its natural hosts. The cat can shed the oocysts for 7 to 12 days. After the sporulation, 
the oocyst becomes infectious to other animals if ingested. The oocyst can survive in the 
environment for approximately one year. For the asexual cycle, almost all animals 
which are intermediate host to this parasite can produce the parasite either in the 
tachyzoite form or cycts (which are transformed from the tachyzoites). Both tachyzoites 
and cycsts are also infectious.
The disease is acute and chronic. Currently there are no effective cures for 
toxoplasmosis. The treatments used are sulfonamides, or a combination therapy of 
sulfonamide and pyrimethamine, spiramycin and clindamycin. However, all these drug 
treatments are needed for the entire life, and as yet no effective vaccine against 
toxoplasmosis has been produced. Another alternative treatment for controlling the 
disease is using antibody. An effective antibody can prevent the progression of the 
disease to critical condition. In this study, an anti-Toxoplasma scFv was transformed 
into plant genome for producing antibody against the protozoa. 
The plant systems were chosen as bio-factories since they have many advantages 
compared to mammalian cell cultures. For instance, the mammalian cell cultures that 
are commonly used in producing antibody have a high risk of human pathogens 
2contamination. There are two different plant hosts used in this study, i.e. banana cell 
suspension and tobacco. The tobacco was used as a model (reference) plant because the 
study on plant made protein (PMP) in tobacco is well established. Additionally, there 
are several biopharmaceutical products that are produced from tobacco that have been 
commercialized. For example, the production of antibody against Hepatitis B by the 
Center for Genetic Engineering and Biotechnology (CIGB), Cuba (Mola et al., 2006).
In this study, the Agrobacterium-mediated transformation is used as a method for 
transforming the transgene into the plant genome because of its single copy gene 
transformation method and its ability to transfect the plant. Moreover, the insertion of 
the transgene is more stable compared to particle bombardment method.
1.2 Objectives
The objectives of this study are;
i. To design gene expression cassettes based on a plant expression 
constructs and pre-cloned genes of a scFv anti-Toxoplasma antibody as 
the gene of interest.
ii. To carry out gene transfer experiments with these cassettes into somatic 
cell embryos of Musa acuminata cv. Berangan and Nicotiana tabacum L. 
cv. SR1 leaf disc.
iii. To determine the levels of expression of the foreign gene in the plants 
using constructs containing different enhancer elements.
3CHAPTER 2:LITERATURE REVIEW
2.1 Toxoplasmosis
Toxoplasmosis is a disease caused by Toxoplasma gondii, which is a species of 
parasitic protozoa in the genus of Toxoplasma. This disease is widespread in humans 
and warm-blooded animals, especially farm animals. Members of the Felidae family are 
the definitive hosts of the Toxoplasma gondii, because they are the only animal that can 
harbour the adults parasites in their intestinal tract. The sexual life cycle of Toxoplasma 
gondii occurs in the cat family, while the asexual life cycle can occur in any other 
warm-blooded animal.
Figure 2.1: Ultrastructure of a Toxoplasma gondii tachyzoite (Ajioka et al., 2001).
2.1.1 Toxoplasma gondii strains
There are three difference strains of this pathogen (type I, II and III), which are 
classified into two groups, virulent and non-virulent. Only type I strain is the highly 
pathogenic; while type II and type III strains were grouped in the non-virulent group. As 
summarized from Maubon et al. in 2008, type I was rarely been isolated but highly 
4virulent. The multiplication rate is high but low in interconversion tachyzoite-bradyzoite. 
The most commonly been isolated strain in Europe and North America is type II which 
is non-virulent with slow rate of multiplication but easier interconversion tachyzoite-
bradyzoite and formation of cysts. While type III is less frequent been isolated if 
compare to type II.
Among these three major strains, the type I strain RH is the first human strain 
which is only found in severe cases of human toxoplasmosis.  The first isolated RH 
strain was by Albert Sabin in USA from a six year old boy who died of toxoplasmosis 
encephalitis in 1939.  The RH strain is highly virulent and caused 100% lethality when 
tessted in laboratory mice (Ajzenberg, 2010). 
2.1.2 Sources of infection
Infection occurs worldwide, but the prevalence is higher in warm and wet 
countries, such as South America, Africa and parts of Asia (Petersen, 2007). The high 
prevalence may also be related to hygiene standards and eating habits. Eating 
undercooked meat and drinking unpasteurized milk and untreated water will increase 
the exposure rate to the infection. Besides this, gardening and husbandry of domestic 
animals also contribute to infection chances, because oocysts of Toxoplasma gondii can 
survive in the moist shaded soil. Another source of the infection is through contact with 
the definitive host, i.e. cats. In many families, cats are kept as pets and this will increase 
the chances of exposure. The sources can be summarized in the Figure 2.2.
5Figure 2.2: Sources of Toxoplasma infection (Ho-Yen, 2005).
2.1.3 Symptoms of toxoplasmosis
The symptoms of the infection include swollen lymph nodes, fever, vague ill 
feeling and sometimes eye pain, blurred vision and sore throat. However, some 
individuals may not show any symptom after infection if they have a healthy immune 
system. 
The acute symptoms are usually shown by newborn babies, especially those born 
with congenital toxoplasmosis. They may exhibit inflammatory lesions that can lead to 
permanent neurological damage, chorioretinis which may lead to blindness, 
hydrocephalus, mental retardation and enlargement of the liver and spleen (Petersen, 
2007).
62.14 Control of toxoplasmosis
There are several means that can be taken in preventing infection by 
toxoplasmosis, such as taking general hygiene precautions. As an example, avoid eating 
raw or undercooked meat or drinking unpasteurized milk, washing of hands after 
handling animal litter trays or gardening. Additionally, reducing contact with cats is 
also a preventive action, especially for pregnant women who are high risk (Ho-Yen, 
2005). There are currently no effective vaccines for this disease. Treatment of 
toxoplasmosis consists of spiramycin, pyrimethamine and sulfadoxine (Elsheikha, 2008) 
all of which are associated with side-effects.
One potential approach for treating the disease post-infection is the use of specific 
therapeutic antibodies. This approach may present an effective way in controlling the 
spread of the disease. In particular it may be applied to carriers of the disease including 
animal carriers such as pet cats. Applications of scFvs as therapeutic agents include as 
reported by Yoshida et. al. in 2003, the bispecific single-chain antibody fragment 
(biscFv) was targeted to the surface protein of human malignant malaria parasite, 
Plasmodium falciparum, and activated the macrophages to kill the parasite. scFv 
antibodies were also used as diagnostic and therapeutic agents, i.e. immunosensors, 
molecular magnetic resonance imaging (MRI), near infrared fluorescence imaging 
(NIRF), anticoagulants, fibrinolytics and intrabodies (Hagemeyer et. al., 2009). In this 
study, an scFv gene coding for a recombinant phage derived anti-Toxoplasma antibody 
will be introduced into a plant expression system to potentially produce the antibody in 
plant cells in large volume.
2.2 Therapeutic proteins
There are two major categories of biotechnology-derived drugs, which are 
antibodies and vaccines. In the antibodies category, these include several forms 
7including monoclonal antibodies, single-chain variable fragments antibodies (scFv), and 
antigen-binding fragments (Fab) all of which are potentially candidates as therapeutic 
proteins.
Recombinant therapeutic proteins are the proteins that are synthesized in living 
organisms, such as bacterial, yeast, mammalian cell cultures and plants. Based on a data 
monitor report, recombinant therapeutics were estimated to contribute $53 billion to the 
market by 2010 (Datamonitor, 2004).
2.2.1 Monoclonal antibodies
Monoclonal antibodies were first studied by Cesar Milstein and Georges Kohler 
in 1975 from B cell hybridomas of mice and was a discovery that subsequently brought 
them the Nobel Prize in Medicine in 1984 (Milstein, 1985; Khöhler, 1985).  
Monoclonal antibodies have been used as the antibody-based therapy agent for 
many diseases due to its monospecificity, homogeneity and consistency (Lipman et al., 
2005). However, they are expensive and time consuming in production. Additionally, 
the risk of toxicity is high as they are produced in mammalian cell cultures which 
predispose it to potentially cause allergic-type reactions (Peterson et al., 2006).
Hence, several different forms of antibody fragments have been developed to 
overcome the limitations of monoclonal antibodies. The antibody fragments that have 
been studied are antigen-binding fragment (Fab), single-chain variable fragments (scFvs) 
and Third Generation (3G) molecules (Nelson, 2010). Monoclonal antibody types were 
shown in Figure 2.3.
8Figure 2.3: Antibody fragment types. Depiction of a full size antibody and various 
antibody fragment types. CH, constant heavy chain; CL, constant light 
chain; IgG, immunoglobulin; Fab, antigen-binding fragment; scFv, single 
chain variable fragment, VH, variable heavy chain; VL, variable light 
chain. (Nelson, 2010).
2.2.2 scFv gene
Typically, antibodies are the immunoglobulin molecules that consist of two 
identical heavy and light chains that joined together by disulfide and non-covalent bond. 
One of the most well researched approaches is in the development of single chain 
variable fragment (scFv) antibodies. A scFv antibody consists of the variable regions of 
heavy and light chain of immunoglobulin, which are joined together by a flexible 
peptide linker. Therefore, the size of the molecule is smaller than the original 
immunoglobulin but it still retains the intact antigen binding site (Ahmad et. al., 2012). 
The scFv antibody with its small molecular size is an attractive candidate because of its 
ease in penetrating the tissue or tumor, its reduced immunogenicity, and also the ease of 
cloning it in bacteria for genetic engineering (Hagemeyer et. al., 2009; Ahmad et. al., 
2012).
92.3 Plant molecular farming
Plant molecular farming refers to the recombinant proteins that are produced by 
genetically-modified plants for pharmaceutical and industrial uses (Breyer et al., 2009). 
Plant expression system plays important role in producing recombinant proteins and 
biopharmaceutical products as it offers several potential advantages. 
First, the cost of producing and processing plant-based recombinant proteins is 
lower compared to the traditional expression system, such as bacterial expression 
system and mammalian cell cultures. Plants offer more economical platforms because 
the process of producing required inexpensive equipment, media or skilled personnel, 
unlike major fermentation-based system (Fischer et al., 2011). The processing 
technology is also more straightforward. 
In addition, plant-based technology could promise safer products compared to 
mammalian cell cultures-based products. The PMP products are considered lower risk 
as there is minimal chances for human pathogen contamination arising from the host 
cell.
Furthermore, plants have the ability to perform post-translation modifications that 
are required for producing functional mammalian proteins (Stoger st al., 2002; Breyer et 
al., 2009). As an example, the proper folding and disulphide bond formation are 
occurred in endoplasmic reticulum (ER) and chloroplast (Daniell et al., 2009).
Using plants as expression platforms also offer the benefit of easy and rapid 
scaling up. The desired recombinant protein can be produced in large scale, once the 
transgenic plants that harbour the gene of interest have been developed (Commandeur et 
al., 2003).
10
2.4 Factors affecting protein expression in plants
Transgenic approaches are being widely studied compared to the traditional 
approaches as they present many advantages in terms of production times and costs as 
described in the previous sections. In addition, production of therapeutic proteins from 
the plants also more cost efficient and easy to store (Daniell et al., 2001; Ma et al., 
2003).
However, there remain some limitations of using plants. One of the major concern 
is the lower yield of recombinant protein production which can be affected by the 
stability of recombinant proteins in plant system, the design of expression constructs or 
system, and the plant host species (Abolade and Ahmadu, 2012; Nagels et. al., 2012). 
There are several factors that cause the instability of recombinant proteins in the plant 
system, including the localization of transgene in plant system and the presence of 
protease naturally in plant system.  For example, as reported by Loos et. al. in 2011, the 
stability and production yield of two monoclonal antibodies (2G12 and HA78) in the 
seeds of Arabidopsis wild type plants. The KDEL-tagging scFv-Fcs of 2G12 and HA78 
were more stable in the plant system compare to the non-subcellular targeting (Loos et. 
al., 2011).
2.4.1 Strategies for preventing proteolysis or increase foreign protein 
accumulation
One of the factors that affect the maximum production of heterologous protein in 
plants is proteolytic activities by the plant defense system. Proteolysis is an important 
and necessary process in all living organisms, because only with the presence of this
process, the damaged, misfolded and harmful proteins will be degraded and release the 
amino acids for other protein synthesis. Hence, proteolysis poses a significant challenge 
to recombinant proteins that are introduced into the cells, because the foreign protein 
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will be treated as harmful to the cells and has been degraded by the proteolytic enzymes. 
Thus, the yield of the recombinant protein will be decreased as well.
To overcome this challenge and establish or increase the accumulation of the 
viable transgene expression level; co-expression of a companion protease inhibitors, 
organelle targeting peptides and tissue targeting peptides have been proposed in recent 
studies (Benchabane et al., 2008; Deng et al., 2003). 
2.4.2 Organelle targeting (ER targeting - KDEL)
There are a number of organelles which are involved in protein synthesis. Hence, 
organelle targeting is a promising approach for enhancing the yield of recombinant 
protein production in plants. The subcellular compartments which are involved are
apoplast, chloroplast, vacuole, cytosol, and endoplasmic reticulum (ER). 
Most of the recent transgenic approaches for expression of foreign proteins in 
plants have utilised the endoplasmic reticulum retention signal also known as the KDEL 
retention sequence in their constructs. The KDEL retention sequence is 21 base pairs 
long, which is 5’-TCTGAGAAAGATGAGCTCTAG-3’. This simple sequence will 
then target the transgene into the lumen of the endoplasmic reticulum (ER) in the plant 
cells. The lumen of the endoplasmic reticulum is the first destination of the cell 
secretory pathway. The protein is later directed to the Golgi apparatus, then transferred 
to the vacuoles and lastly to the cell surface (Okamoto et al., 2003). In this study, KDEL 
retention sequence is fused to the gene of interest so that the stability and the 
accumulation rate of the protein expression will be improved. 
2.4.3 Co-expression with protease inhibitor (BBI)
Other than organelle targeting, co-expression with protease inhibitor is another 
alternative method to maximize the production of protein. 
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There are many protease inhibitors that have been found in plants. The 
mechanism of action of plant protease inhibitors still remains unclear. Based on Plant-PI 
database, plant protease inhibitor can be categorized into 10 families. The families 
consists of the Bowman-Birk serine proteinase inhibitors (BBI), Cereal trypsin/alfa 
amylase inhibitors, Cysteine proteinase inhibitors, Metallocarboxypeptidase inhibitors, 
Mustard trypsin inhibitors, Potato type I inhibitors, Potato type II proteinase inhibitors, 
Serpin, Soybean trypsin inhibitors(Kunitz) and Squash inhibitors (De Leo, 2002).
Different protease inhibitors have different functions in the plants systems. The 
endogenous proteinases are involved in the plant development and growth. Therefore, 
the protease inhibitor that was chosen for the study should not affect the plant growth. 
There are few studies which showed the successfully of increasing the protein level by 
co-expression with protease inhibitors. Rivard and co-workers have reported that the 
level of cathepsin D-like and ribulose 1,5-biphosphate carboxylase/oxygenase 
hydrolysing activities was decreased in the leaf crude protein of transgenic potato in the 
presence of either tomato cathepsin D inhibitor (CDI) or bovine aprotinin. Therefore, 
the recombinant protein that was recovered from the transgenic potato is higher 
compared to normal (control) potato (Rivard et al., 2006).  Another research done by 
Komarnytsky et al. proved that the Bowman-Birk serine proteinase inhibitor (BBI) was 
able to stabilize the recombinant antibodies in tobacco roots. Therefore, in this study, 
we adapted the technique by using BBI to analyse its ability to stabilize the anti-
Toxoplasma antibody in the banana cells and tobacco plants. 
2.5 Plant expression vector
Plant expression vector plays the vital role in transforming the transgene into the 
plant host. Therefore, a plant expression vector must contain several fundamental 
features which includes promoter, origin of replication, multiple cloning sites, antibiotic 
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resistance marker and reporter gene (Slater et al., 2003). In this study, pCambia1304 
was used as the backbone of the construct. The reporter genes of pCambia1304 are 
gusA and mgfp5 (as showed in Figure 2.4).
Figure 2.4: Map of pCambia1304 vector (obtained from www.cambia.org).
2.5.1 Reporter genes
Reporter genes or non-selectable marker genes in plant expression vector are the 
tools that are used for analyzing the host cells ability to take up the gene of interest. 
Reporter genes were used to improve transformation systems and the efficiency of 
recovering transgenic plants by allowing the visual detection of transformed tissues 
(Miki and McHugh, 2004). An ideal reporter gene is easy to assess and non-destructive 
to the assay system. It will be more excellent if the reporter gene has no or only a little 
endogenous activity in the plant to be transformed (Slater et al., 2003).There are several 
reporter genes that are used in plant expression vectors, such as β-glucuronidase, green 
NcoI Bgl II
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fluorescent protein, luciferase genes and chloramphenicol acetyltransferase. In this 
study, the β-glucuronidase and green fluorescent were used for transient assay.
2.5.1.1 β-glucuronidase (GUS)
β-glucuronidase (GUS) is an enzyme that found in the Escherichia coli, which 
encoded by uidA gene (Hull and Devic, 1995). It was first developed in plant systems 
by Richard Anthony Jefferson in 1987. Since then, it is widely been used as a reporter 
gene in plant molecular biology. The common assays that were carried out with this 
reporter gene are fluorometric assay and GUS histochemical staining.
Fluorometric assay is used to analyze the activity of transgene expression through 
quantitative. The reaction is carried out by adding the substrate, 4-methylumbelliferyl-
beta-D glucuronidase (MUG) before measurement with a fluorometer.
GUS histochemical staining is a common assay used for transient expression. In 
GUS histochemical staining, the substrate, 5-bromo-4-chloro-3-indolyl glucuronidase 
(X-Gluc) was hydrolyzed and produces an indigo-blue precipitation.
2.5.1.2 Green fluorescent protein (GFP)
Green fluorescent protein is a protein that is found in jellyfish, Aequorea victoria, 
which consists of 238 amino acids.  It was first studied by Osamu Shimomura in 1960s, 
where he found that the jellyfish glows green because the GFP protein had absorbed the 
blue light from the aequorin, (jellyfish photoprotein, which glows blue with the 
presence of calcium) and the ultraviolet light. This protein needs only oxygen (which 
are readily in most living organisms), without other additional substrate or co-factor to 
react in the fluorophore. Besides this, it is also a non-destructive technique that can be 
visualized in vivo (Hibberd et al., 1998), and expressed shortly after the transformation.
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2.6 Agrobacterium-mediated transformation 
Genetic transformation in plants are the tools that are used for transferring the 
desired gene into plant cells and allowing it to integrate into the plant’s genome 
enabling it to be passed on to the next generation. There are two categories of the 
genetic transformation methods, which is direct gene transfer and indirect gene transfer. 
The direct gene transfer methods include particle bombardment, electroporation, silicon 
carbide fibres-whiskers, microinjection, polyethylene-mediated transformation and 
macroinjection. While, the indirect gene transfer method is by Agrobacterium-mediated 
transformation.
In this study, Agrobacterium-mediated transformation is used to transfer the 
transgene into banana cell suspension and tobacco leaf disc, rather than the biolistic 
technique. This method is an effective indirect gene transfer protocol that has been 
widely used in recent years compared to biolistic technique because of the problem of 
losing the inserted DNA randomly.
Agrobacterium-mediated transformation is the most common and efficient method 
in plant genetic engineering. The main principle in this method is the use of 
Agrobacterium tumefaciens, a soil plant pathogenic bacterium. It utilises its T-DNA 
region in transferring the foreign DNA into plant cells through homologous 
recombination. There are several essential steps for transferring the transgene into plant 
cells. Firstly, Agrobacterium colonizes on the plant cell surface, and then induces the 
bacterial virulence systems in the presence of phenolic compounds, such as 
acetosyingrone, produced by the wound of the plants. In the presence of phenolic 
compounds, the vir gene will be activated and therefore generate the T-DNA transfer 
complex. Thus, the transgene that are placed between the T-DNA borders will be 
transferred into the plant cell as single strand DNA and integrated into plant genome 
(De la Riva et al., 1998).
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Even though, Agrobacterium-mediated transformation is not necessarily suitable 
to all types of explants and plant species, it is still widely used because of its remarkable 
advantages over the direct gene transformation methods. Agrobacterium-mediated 
transformation can avoid the formation of mosaic plants because of it is single cell 
transformation system. Additionally, the transgene that is transferred through 
Agrobacterium is low in copy number and therefore can reduce the problem of co-
suppression or instability of the transgene in the cells host. 
2.7 The plant host
Plants are popularly used as protein factories in many current studies, because 
they offer significant advantages over the classical expression system (such as bacterial 
and animal cell cultures). They especially have the potential to produce the desired 
proteins more economically. Many proteins were produced by transgenic plants and 
have been used, such as glucocerebrosidase and granulocyte-macrophage colony 
stimulating factor (Giddings, 2001). However, some plant hosts have biosafety issues 
because of their natural promiscuous nature which allow for outcrossing with wild 
relatives. These plants include tobacco and maize which are the popular plant systems 
that are often been used. Therefore, a naturally sterile system will be an attractive 
alternative to overcome this problem. 
In this study, banana, Musa acuminata cv.Berangan, was chosen as the plant host 
because of its male sterility which allows for easier biosafety containment design. While, 
tobacco was used as a conventional model and plant reference for foreign gene 
expression, since it has been successfully produced heterologous protein in other studies 
(Llop-Tous et al., 2011; Yakoby et al., 2006). 
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2.7.1 Banana cell suspensions
The stable integration, ability to regenerate from a single cell to complete plantlet 
and also the expression of desired transgene in plant host are the fundamental 
requirements.
In this study, the candidate tissues for genetic engineering of the banana are 
embryogenic cell suspensions, which regenerated through somatic embryogenesis. This 
cell has a potential to prevent formation of chimeras. Somatic embryogenesis is an 
asexual form of plant propagation which can form a complete plant under a mimic of 
natural condition. The plantlets that are produced from somatic embryogenesis will 
have the same genetic makeup. Therefore, all transformed cells suspension will be able 
to express the same gene of interest and may lead to higher protein production.
2.7.2 Tobacco leaf discs
Tobacco is widely used as plant expression system in producing recombinant 
proteins, because of its unique characteristics. Tobacco is a short life cycle plant; it only 
takes 3 months to grow from seed until flowering. Besides that, it is a non food/feed 
crops. This particular trait makes it the choice as a biofactory because there is no food 
chain contamination issue involved. Thus, it has lowered the risk assessment challenges. 
Tobacco is also a well-studied plant and is easily transformed. The first transgenic 
plant is tobacco which produced antibody targeting gum disease was developed by the 
company Plant Biotechnology of CaroRxTM (Ganapathi et al., 2004; Wycoff, 2004).
Furthermore, tobacco is a cost effective and economically productive biofactory. 
It has the largest biomass yield on the earth after sugar cane. The track record in plant-
made pharmaceuticals (PMP) research is also positioning it to be the forefront candidate 
as a PMP biofactory (Stoger et al., 2002).
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2.8 Biosafety and risk assessment
Plant expression system provides an alternative platform with several potential 
advantages over traditional expression systems. However, PMPs lead to the challenges 
and risks of environmental, animal/human health and safety issues. The challenges are 
included gene flow, activation of antibiotic resistant genes, spontaneous formation of 
superweed, toxicity, allergenicity and anti-nutritional effects (Talas-Ogras, 2011). Thus, 
risk assessments need to be carried out on all transgenic plants in a scientific and 
transparent manner in monitoring the possible risks. 
Since there are a lot of challenges and possible risk issues, biosafety regulations 
and risk assessment are important in addressing the strategies to minimize and limit the 
potential environment and animal/human health impacts. For instance, the Cartagena 
Biosafety Protocol (CBP) of the Convention on Biological Diversity was emphasized on 
the regulations of transboundary movement between countries, handling and use of 
living modified organisms among the signatory countries in 2000 (Talas-Ogras, 2011).
In different countries, there are different regulations and organizations that 
involved. For example, in European Union (EU), the legalization is focus on the genetic 
engineering processes and products; while, in United States (US), the legalization is 
only products based (Talas-Ogras, 2011). In Malaysia, PMPs are regulated under the 
Malaysian Biosafety Act 2007 (www.nre.gov.my).
PMP products will be the trend in the future market. Therefore, more elements
must be taking into the account of risk assessment, such as, characteristic of plant host, 
production area and handling practices (Breyer et al., 2009). The consultation and 
advice from experts of different fields like molecular biology, toxicology, dietetics and 
genetics must be considered as well for producing the safer and useful PMP products.
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CHAPTER 3:MATERIALS & METHODS
3.1 Materials 
The experiments for this study involved the construction of a cassette containing 
several genes and sequences with the plant transformation vector, pCambia as a 
backbone. The genes are an anti-Toxoplasma scFv, the Bowman-Birk Serine Proteinase 
Inhibitor (BBI) sequence and the KDEL retention sequence.
The anti-Toxoplasma scFv gene sequences, scFv64 (Accession number: 
JN104603, NCBI gene bank) and scFv130 (Accession number: JN104602, NCBI gene 
bank) were obtained from a previous study (Lim, 2013). The fragments were amplified 
from a pCANTAB 5E vector. Briefly, E.coli carrying the plasmid pCANTAB 5E 
containing these scFv fragments were cultured on standard solid media with 100µg/ml 
ampicillin. A colony PCR screen was carried out to select the positive clones by using 
pCANTAB 5E_S1 primer and pCANTAB 5E_S6 primer (as stated in Table 3.2).
The Bowman-Birk Serine Proteinase Inhibitor (BBI) gene of the Musa sp. and 
KDEL retention sequence were synthesized based on information from gene bank, 
NCBI (Accession number: 127893 and AX164111, respectively) by Vivantis (M) Sdn. 
Bhd. 
Two different pCambia plasmids were used in this study, which are the original 
pCambia1304 (www.cambia.org) for constructing scFv64 and the modified 
pCambia1304 plasmid, i.e pCambia1304AvrII, which was used to construct scFv130 
clone. The protocol for modification of the pCambia1304 is as described in Section 
3.2.4.3.
The plant hosts for this study were Musa acuminata cv. Berangan cell suspensions 
and Nicotiana tabacum L. cv. SR1. Musa acuminata cv. Berangan cell suspensions 
were used to express the scFv64 and scFv130 against Toxoplasma antigen. While 
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Nicotiana tabacum L. cv. SR1 was the platform used for expressing scFv130 against 
Toxoplasma antigen. Both plants were provided by Professor. Dr. Norzulaani Khalid 
from the Plant Biotechnology Incubator Unit (PBIU), CEBAR, University Malaya.
The overview of the project is as shown in Figure 3.1.
Figure 3.1: Overview of the project.
3.2 Methods
3.2.1 Plasmid extraction
The protocol for plasmid extraction from E.coli cells was modified from 
Sambrook, 2001. Firstly, a single colony was inoculated into 10µl sterile LB broth with 
100µg/µl kanamycin and incubated overnight at 37ºC with 220rpm. The overnight 
culture was transferred into a 15ml falcon tube and centrifuged at 6000rpm for 15 
minutes. The supernatant was discarded and 200µl of ice-cold Solution I was added into 
the tube. After that, 200µl of Solution II were added and incubated at room temperature 
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for 4 minutes. Next, 200µl of ice-cold Solution III were added and incubated on ice for 
15 minutes. Then, the mixture was centrifuged at 13000rpm for 10 minutes. The 
supernatant layer was transferred to a new 1.5ml microcentrifuge tube. 
Then, 1µl of RNase A 20mg/ml were added to the supernatant and incubated at 
37ºC for 2 hours. After incubation, 600 µl of phenol was added and vortex. Then, the 
mixture was centrifuged at 13000rpm for 3 minutes. The aqueous layer was transferred 
into another new microcentrifuge tube and 600µl chloroform was added. The mixture 
was vortex and centrifuged at 13000rpm for 3 minutes. Then, 400µl of aqueous layer 
was transferred to new 1.5ml microcentrifuge tube.
Finally, the DNA was precipitated with 0.1 volume of 3M sodium acetate and 2.5 
volumes of ethanol. The mixture was incubated on ice for 20 minutes and centrifuged at 
13000rpm for 15 minutes. The supernatant was discarded and 1ml of 70% ethanol was 
added. The mixture was centrifuged again at 13000rpm for 5 minutes. After that, the 
pellet was dried by using vacuum centrifuge (DNA PLUS HETO). The dried pellet was 
dissolved in 50µl sterile distilled H2O and stored at -20ºC.
The OD 260/280 assay was carried out by Eppendorf Biophotometer to determine 
the concentration of DNA sample in solution. The reading at 260nm is indicates the 
concentration of nucleic acid; while, reading at 280nm indicates the amount of protein 
in the sample. The ratio of absorbance, A260/280, for pure DNA should be in the range of 
1.8-2.0; however, the range of 1.7-2.0 was considered sufficient purity.
For measuring DNA concentration, 5µl of samples were mixed with 495µl sterile 
distilled H2O. The diluted samples were measured at wavelength of 260nm and 280nm. 
The readings were taken against a blank of 500µl sterile distilled H2O. 
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3.2.2 PCR and primers
The oligonucleotide primers that used in PCR screening, PCR amplification, PCR 
of RE site insertion and PCR confirmation were lists in the following tables (Table 3.2, 
Table 3.3 and Table 3.4). They are designed by using Primer 3.0 software. While, 
oligonucleotide primers that used for Real-time PCR were designed by using Primer 
Express 3.0 software and listed in Table 3.5.
The regime of all thermal cycling condition is stated in the following table.
Table 3.1: The thermal cycling condition that were used in the experiments.
Condition Temperature, ºC Time, minutes No. of cycle
Initial denaturation 94 4 1
Denaturation 94 1
35Annealing Depend on primer set 1
Extension 72 1
Final extension 72 10 1
Final hold 25 10 1
PCR screening was carried out on the colonies that formed after transformation. 
The colonies were selected from overnight cultured LB agar plate and picked up by 
toothpick to make a library on new LB agar plate. The toothpick was dabbed in a PCR 
tube that contains 50µl distilled water. Then, the library plate was incubated at 37ºC for 
overnight; while, the PCR tubes with bacteria were boiled at 99ºC for 10 minutes and 
used as template for PCR screening.
The PCR products that obtained after amplification and RE site insertions were 
performed with purification for further use. PCR purification was carried out according 
to the provided protocol of QIAquick PCR Purification kit from Qiagen.
Five volumes of Buffer PBI were added to one volume PCR product and mix well. 
Then, the mixtures were transferred to QIAquick spin column which placed into a 
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provided 2ml collection tube. The mixtures were centrifuged at high speed for 1 minute. 
The flow-through was discarded and 750µl of the Buffer PE were added to the spin 
column. Centrifugation for 1 minute at high speed is carried out. The flow-through was 
discarded and centrifuge for 1 minute again.
After that, the spin column was transferred into a new 1.5ml microcentrifuge tube. 
Then, 30µl of Buffer EB were added and incubated for 1 minute before centrifuge at 
high speed for 1 minute. The elution product was stored at -20ºC.
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Table 3.2: List of primers that were used for PCR screening.
Primer Set Sequence length
Annealing 
temperature, ºC
Expected size of 
PCR product, bp
pCANTAB 5E_S1
pCANTAB 5E_S6
5’-CGGGGAGCCGGCCGAGCTCG-3’
5’-GCCTGCGGCCGCACTAGTGACAGA-3’
20
24
56.0 ~850
57BBIKDEL_F
57BBIKDEL_R
5’-GTTTTCCCAGTCACGACGTT-3’
5’-AGTGAGCGCAACGCAATT-3’
20
18
59.3 ~800
gfp_F
gfp_R
5’-GGCTCGAGGACCATGGTAGATCTGACTAGTA-3’
5’-CTCGAGTCTAGAGGGGTTTCTACAGGACGTAAACT-3’
31
35
58.0 ~750
1304SK_F
1304SK_R
5'-GAGAGAACACGGGGGACTC-3'
5’-TCCATGAAAAGTTCTTCTCCTTT-3’
19
23
58.0 ~1500
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Table 3.3: List of primers that were used in PCR amplification and RE site insertion.
Primer Set Sequence
Number of 
nucleotides
Annealing 
temperature, ºC
Expected size of 
PCR product, bp
scFv64NcoI_F
scFvHindIII_R
5’- CGAATTGCCATGGTGATGACC -3’
5’- TATGAGGTTAAGCTTTTGCTAAAC -3’
21
24
42.0 ~800
scFv130AvrII_F
scFvHindIII_R
5- CGACATCCTAGGTGTATGACCCAG -3’
5’- TATGAGGTTAAGCTTTTGCTAAAC -3’
24
24
42.0 ~800
57BBIKDEL_F
57BBI_R
5’- GTTTTCCCAGTCACGACGTT -3’
5’-CGTGAGCGCAACGCAATTA-3’
20
19
59.3 ~800
57BBI_F
57BBI_R
5’-GCTCATCTTTCTCAGATCTTT-3’
5’-CGTGAGCGCAACGCAATTA-3’
21
19
59.3 ~800
35SBamHI_F
35SNcoI_R
5’-GTACCCGGGGATCCTCTAGAGTCG-3’
5’-CTACCATGGCCTAGGTCAAGCGCTAGAGTC-3’
24
30
42.0 ~800
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Table 3.4: List of primers that were used in PCR confirmation.
Primer Set Sequence
Number of 
nucleotides
Annealing 
temperature, ºC
Expected size of 
PCR product, bp
1304SK_F
1304SK_R
5'-GAGAGAACACGGGGGACTC-3'
5’-TCCATGAAAAGTTCTTCTCCTTT-3’
19
23
58.0 ~1500
gfp_F
gfp_R
5’-GGCTCGAGGACCATGGTAGATCTGACTAGTA-3’
5’-CTCGAGTCTAGAGGGGTTTCTACAGGACGTAAACT-3’
31
35
58.0 ~750
NtAct_F
NtAct_R
5’-AGTCCTCCTTACTGAAGCGCCT-3’
5’-GAATGGCAACGTACATAGCTGG-3’
22
22
60.0 ~400
Actin9_F
Actin9_R
5'-CTATTCTCCGCTTTGGACTTGGCA-3'
5'-AGGACCTCAGGACAACGGAAACG-3'
24
23
60.0 ~250
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Table 3.5: List of primers that were used in Real-time PCR.
Primer Set Sequence
Number of 
nucleotides
Expected size of 
PCR product, bp
Actin9_F
Actin9_R
5'-CTATTCTCCGCTTTGGACTTGGCA-3'
5'-AGGACCTCAGGACAACGGAAACG-3'
24
23
~400
TG13090_F
TG13090_R
5’-TTCCTCCAGCACAGCCTACA-3’
5’-TAAGCAAACCCATCCCCTCTT-3’
20
35
~90
gfp180_F
gfp180_R
5’-CAAGCAAAAGAACGGCATCA-3’
5’-CTCTTTTCGTTGGGATCTTTCG-3’
20
22
~180
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3.2.3 Digestion
Different restriction enzymes combinations were used throughout the experiments, 
(as mentioned in Section 3.2.4) based on the design of the constructs. In general, the 
reaction was carried out by incubation at 37 ºC for one hour.
Then, the restriction enzyme digestion products were purified using QIAquick Gel 
Extraction Kit (Qiagen) based on the provided protocol. The electrophoresed DNA 
fragment was excised from agarose gel under UV light (Vilber Lourmat). The gel slice 
was weighed and 3 volumes of Buffer QG were added before incubation at 50ºC for 10 
minutes. After that, 1 volume of isopropanol was added and mixed well. 
Then, the mixture was transferred into the spin column which was placed in the 
provided 2ml collection tube, and centrifuged at high speed for 1 minute. The flow-
through was discarded and 500µl of Buffer QG were added and centrifuged for a further 
1 minute at high speed to remove all traces of agarose. Then, 750µl of Buffer PE were 
added and centrifuged for 1 minute at high speed. After that, the flow-through was 
discarded and centrifuged for another 1 minute at high speed.
The QIAquick column was placed in a new 1.5ml microcentrifuge tube. Then, 
30µl of the Buffer EB were added and incubated for 1 minute before centrifuge at high 
speed for 1 minute. The purified DNA fragment was stored at -20 ºC.
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3.2.4 Preparation of construct
3.2.4.1 pToxo64BBIKDEL
Figure 3.2: Construct of the gene of interest with the restriction enzyme sites,
pToxo64BBIKDEL. (Not to scale)
Plasmid pCambia1304 vector was isolated (as mentioned in Section 3.2.1) and 
treated with restriction enzymes digestion (as showed in Table 3.6).
Colonies of scFv64 antibody fragments from LB agar plate were screened with 
PCR using pCANTAB 5E_S1 and pCANTAB 5E_S6 primers (referred to Table 3.2). 
Then, colonies which showed positive results in PCR screening were selected and 
inoculated in 10ml LB broth with 100µg/ml ampicillin. Plasmid of scFv64 antibody 
fragment was isolated using the protocol that stated in Section 3.2.1. The plasmid was 
used as template for PCR optimization and amplification using scFv64NcoI_F and 
scFvHindIII_R (referred to Table 3.3). Then, the products were performed with 
purification (as mentioned in Section 3.2.2) and restriction enzymes digestion.
For BBIKDEL gene fragment, PCR optimisation was carried out to optimise the 
annealing temperatures (50ºC - 60ºC) of 57BBIKDEL_F and 57BBIKDEL_R primers 
(referred to Table 3.2), with plasmids containing the BBIKDEL gene fragment that were 
commercially-synthesized (Vivantis. Sdn. Bhd.). The plasmid with BBIKDEL gene 
fragment was transformed into E.coli competent cells and cultured on agar plate with 
100µg/ml ampicillin. Colonies that formed after transformation were screened using 
57BBIKDEL_F and 57BBIKDEL_R with 59.3ºC as their optimum annealing 
temperature. Colonies with positive results were inoculated in 10ml LB broth with 
100µg/ml ampicillin and plasmid was isolated based on the protocol as stated in Section 
scFv64 BBI KDEL BglIINcoI HindIII
678bp 606bp 21bp
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3.2.1. The BBIKDEL gene fragment was then amplified from the plasmid using primers 
57BBIKDEL_F and 57BBI_R (stated in Table 3.3) with 59.3ºC as annealing 
temperature. The PCR amplification products were purified (as stated in Section 3.2.2) 
and treated with restriction enzymes digestion (see Table 3.6).
Table 3.6: List of restriction endonucleases and buffers that were used to digest 
components for constructing pToxo64BBIKDEL.
Then, the digestion products were purified with QIAquick Gel Extraction Kit (as 
mentioned in Section 3.2.3) and ligation was performed (referred to Table A6 in 
AppendixA6). The ligation mixture was incubated at 22ºC for 1 hour before 
transformation into E.coli competent cells (as mentioned in Section 3.2.6.1). 
Transformation products were cultured on LB agar plate with 100µg/ml kanamycin and 
incubated at 37ºC overnight. Colonies from overnight cultures were selected and 
screened with primers 1304SK_F and 1304SK_F (as shown in Table 3.2). Then, 
plasmids from the colonies which showed expected result in PCR screening was
isolated (as in Section 3.2.1).
Sample Enzyme Enzyme 10 x Restriction buffer
pCambia1304 Nco I Bgl II NEBuffer 3
scFv64 fragment Nco I Hind III NEBuffer 2
BBI gene with KDEL Hind III BglII NEBuffer 2
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3.2.4.2 pToxo64BBI
Figure 3.3: Construct of the gene of interest with the restriction enzyme sites,
pToxo64BBI.(Not to scale)
The pCambia1304 vector and scFv64 antibody fragment were prepared as stated 
in Section 3.2.4.1.
The BBIKDEL gene fragment was used as template to amplify BBI gene 
fragment with primers 57BBI_F and 57BBI_R (as stated in Table 3.3) and the PCR 
amplification products were purified with the protocol that mentioned in Section 3.2.2 
before perform with restriction enzymes digestion.
The digestions were carried out based on combinations in Table 3.7. Then, the 
experiments were carried out as stated in Section 3.2.4.1.
Table 3.7: List of restriction endonucleases and buffers that were used to digest 
components for constructing pToxo64BBI.
Sample Enzyme Enzyme 10 x Restriction buffer
pCambia1304 Nco I Bgl II NEBuffer 3
scFv64 fragment Nco I Hind III NEBuffer 2
BBI gene Hind III Bgl II NEBuffer 2
scFv64 BBI BglIINcoI HindIII
678bp 606bp
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3.2.4.3 pToxo130BBIKDEL
Figure 3.4: Construct of the gene of interest with the restriction enzyme sites,
pToxo130BBIKDEL.(Not to scale)
The construct, pToxo130BBIKDEL was prepared as mentioned in Section 3.2.4.1. 
However, the pCambia1304 vector was modified by PCR with 35SBamHI_F and 
35SNcoI_R (referred to Table 3.3) to add new restriction enzyme sites, AfeI&AvrII. The 
modified pCambia1304 vector was named as pCambia1304AvrII. Additionally, the 
scFv130 antibody fragment was also used in place of the scFv64 antibody fragment. 
The scFv130AvrII_F and scFvHindIII_R (referred to Table 3.3) were used to amplify 
the desired fragment. Then, all the fragments were treated with restriction enzymes 
digestion. The combination restriction enzymes used is as shown in Table 3.8.
Table 3.8: List of restriction endonucleases and buffers that were used to digest 
components for constructing pToxo130BBIKDEL.
Sample Enzyme Enzyme 10 x Restriction buffer
pCambia1304AvrII Avr II BglII NEBuffer 2
scFv130 antibody fragment AvrII Hind III NEBuffer 2
BBI gene with KDEL Hind III BglII NEBuffer 2
711bp 606bp 21bp
scFv130 BBI KDEL BglIINcoI HindIII
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3.2.4.4 pToxo130BBI
Figure 3.5: Construct of the gene of interest with the restriction enzyme sites,
pToxo130BBI.(Not to scale)
The construct, pToxo130BBI was prepared as described in Section 3.2.4.1. The 
combinations of restriction enzymes digestion are as shown in Table 3.9.
Table 3.9: List of restriction endonucleases and buffers that were used to digest 
components for constructing pToxo130BBI.
3.2.4.5 Verification of construct
The plasmid of the constructs (pToxo64BBIKDEL, pToxo64BBI, 
pToxo130BBIKDEL and pToxo130BBI) was digested with restriction enzyme, NdeI, 
(referred Table 3.10) and send for sequencing to confirm the integration of the desired 
genes into the pCambia1304 or pCambia1304AvrII vector. 
Sample Enzyme Enzyme 10 x Restriction buffer
pCambia1304AvrII Avr II BglII NEBuffer 2
scFv130 antibody fragment AvrII Hind III NEBuffer 2
BBI gene Hind III Bgl II NEBuffer 2
678bp 606bp
scFv130 BBI BglIINcoI HindIII
34
Table 3.10: List of constructs that were digested with NdeI.
3.2.5 Competent cell preparation
3.2.5.1 E.coli
The bacterial stocks of competent cells (E.coli JM109 strain) were cultured in 
10ml fresh antibiotic free LB broth at 37ºC with 200rpm for overnight. Then, 1ml 
overnight culture was sub-cultured in 20ml fresh antibiotic free LB broth. The OD600nm 
of the culture was taken in the interval times.
When OD600nm of the culture reached ~ 0.5, the culture was transferred to a 50ml 
centrifuge tube and incubated on ice for 30 minutes. After incubation, the culture was 
centrifuged at 3000rpm for 5 minutes at 4ºC. The supernatant was discarded and 15ml 
of TFB I solution were added to resuspend the pellet. The mixture was incubated on ice 
for 20 minutes before centrifugation at 3000rpm for 5 minutes at 4ºC. Again, the 
supernatant was removed and the pellet was resuspended in 500µl TFB II solution. 
Then, 100µl of freshly prepared competent cells were aliquoted to ice-cold sterile 
microcentrifuge tubes and frozen in liquid nitrogen before store at -80ºC. 
Constructs Enzyme 10 x Restriction buffer
pCambia1304 NdeI NEBuffer 4
pToxo64BBI NdeI NEBuffer 4
pToxo64BBIKDEL NdeI NEBuffer 4
pToxo130BBI NdeI NEBuffer 4
pToxo130BBIKDEL NdeI NEBuffer 4
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3.2.5.2 Agrobacterium tumefaciens
The bacterial stock of Agrobacterium sp. strain LBA4404 competent cells was 
streaked onto an LB agar plate with 50µg/ml rifampicin and incubated at 28±1ºC for 2 
days. 
After 2 days, a single colony of the Agrobacterium sp. was picked to inoculate 
into 5ml sterile LB broth with 50µg/ml rifampicin and incubated in 28ºC for overnight 
with 200rpm. Then, 2ml overnight culture were transferred into 50ml fresh antibiotic 
free LB broth and incubated at 28±1ºC with 200rpm until the OD600nm reach ~0.5.
After that, the cultures were transferred into 50ml centrifuge tubes and centrifuged 
at 5000rpm for 10minutes at 4ºC. The supernatant was discarded and the pellet was 
resuspended in 20ml ice-cold 1mM HEPES (pH 7.0). Then, the mixture was centrifuged 
at 5000rpm for 10 minutes at 4ºC. The wash step with 20ml ice-cold 1mM HEPES and 
centrifugation were repeated for 2 times. Finally, the pellet was resuspended in 500µl 
ice-cold 10% glycerol. Then, 100µl of freshly prepared competent cells were aliquoted 
to ice-cold sterile microcentrifuge tubes and frozen in liquid nitrogen to store at -80ºC 
before use.
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3.2.6 Transformation into competent cell
3.2.6.1 E.coli
The freshly prepared competent cells, E.coli strain JM109 (Section 3.2.5.1) were 
thawed on ice and the ligation mixture was chilled on ice. After thawing, 2µl ligation 
mixture was added to 100µl competent cells and mixed gently. The mixture was 
incubated on ice for 20 minutes before being heat shocked at 42ºC for 45 seconds. After 
heat shock, the mixture was chilled on ice for 5 minutes. Then, 900µl of fresh LB broth 
was added to the mixture and incubated for 1 hour at 37ºC. The transformation products 
were cultured on LB agar plate with 100µg/ml kanamycin and incubated at 37ºC for 
overnight.
3.2.6.2 Agrobacterium tumefaciens
The freshly prepared Agrobacterium sp. strains LBA4404 competent cells (Section 
3.2.5.2) were thawed on ice and the plasmids of the construct were chilled on ice. Then, 
5µl plasmids were added to 100µl competent cells and mixed gently. The mixture was 
incubated on ice for 30 minutes before freeze in liquid nitrogen for 1minute. After 
frozen, the mixtures were immediately thawed at 37ºC for 4 minutes. Then, the mixture 
was chilled on ice for 1 minute before added 900µl of fresh LB broth and incubated at 
28±1ºC for 2 hours. The transformation products were cultured on LB agar plate with 
50µg/ml rifampicin and 100µg/ml kanamycin. The culture plate was incubated at 28ºC 
for 2-3 days.
3.2.7 Agrobacterium-mediated transformation into plant host
3.2.7.1 Banana cell suspensions
An Agrobacterium sp. colony with each construct (pToxo64BBIKDEL, 
pToxo64BBI, pToxo130BBIKDEL, and pToxo130BBI) was inoculated in 3ml LB 
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broth with 100µg/ml kanamycin and 50µg/ml rifampicin. The inoculants were 
incubated at 28±1ºC with 220rpm for overnight. As for experiment control, 
pCambia1304 vector was used and transformed with the same procedure.
Then, the overnight cultures were sub-cultured into 30ml LB broth and grow at 
same condition for another 6 hours. After that, the cultures were centrifuged at 4ºC with 
5000rpm for 10 minutes. The supernatant was removed and the pellet was resuspended 
in 1ml M2 medium supplemented with 100µM acetosyringone. 
Seven days post subculture cell suspensions were transferred into 50ml Falcon 
tube to adjust the settled cell volume: liquid M2 medium ratio approximately 1:5. Cells 
aggregate were then resuspended in M2 medium and 500µl of the cell cultures were 
aliquoted into 10ml of M2 medium.
The aliquoted cell suspensions were inoculated with 1ml of Agrobacterium sp. 
cultures and incubated at 28±1ºC in dark with 200rpm for 30 minutes. After 30 minutes, 
the media containing the Agrobacterium sp. cultures were removed and replaced with 
10ml M2 medium supplemented with 100µM acetosyringone. Then, the inoculated cell 
suspensions were co-cultivated in the dark at 28±1ºC with gentle shaking at 80 rpm for 
3days. After co-cultivation, M2 medium with 50µg/L cefotaxime was used to replace 
the co-culture media to eliminate Agrobacterium sp. 
After 48hours, M2 medium with 50µg/L cefotaxime was removed and M3 media 
was added. The inoculated cells were maintained in the dark with M3 media and the 
media changed every 2 week intervals until somatic formation was observed. An 
aliquote of the cells were also transferred into 1.5ml microcentrifuge tube for GUS 
histochemical staining.
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3.2.7.2 Tobacco leaf discs
The tobacco plants were maintained in MSO media and changed at one month 
intervals. For Agrobacterium-mediated transformation, 1month old leaves were cut into 
~1cm² and put on TSM media for 2 days. An Agrobacterium sp. colony with each 
construct (pToxo130BBIKDEL and pToxo130BBI) was inoculated in individual 10ml 
LB broths with 100µg/ml kanamycin and 50µg/ml rifampicin. The inoculants were 
incubated at 28±1ºC and shaken at 220rpm overnight.
The overnight Agrobacterium sp. cultures were centrifuged at 5000rpm for 
10minutes. The supernatant was removed and the pellet resuspended in 10ml co-culture 
media. The pre-culture explants were transferred into the Agrobacterium sp. culture and 
incubated for 10minutes with gentle shaking. After that, the inoculated explants were 
blotted dry on filter paper before transfer into TSM media and co-cultivation in the dark 
for 3 days. After co-cultivation, the inoculated explants were transferred to TSM 
selection media and kept in 16 hours light: 8 hours dark photoperiod. The TSM 
selection media was changed every week until the formation of the shoots. 
The shoots were excised from explants and transferred to TRM selection media. 
The shoots in TRM media were maintained until root formation. Then, the plantlets 
were transferred to soil. Some of the excised shoots were assayed with GUS 
histochemical staining for confirmation of successful transformation.  
As an experimental control, pCambia1304 vector was used and transformed with 
the same procedure.
3.2.8 Analysis of transgenes
3.2.8.1 GUS assay
The inoculated banana cell suspensions were centrifuged at 13000rpm for 1minute. 
The remaining media was removed by pipetting. Then, the cells were immersed in GUS 
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histochemical assay reagents (as in Table A7, Appendix A9) and incubated at 37ºC
overnight. The samples were then fixed in FAA solution. The stained cells were 
examined under contrast phase light microscope (Zeiss) and images were captured by 
using a microscope adapted Nikon digital camera (COOLPIX995).
While, for the tobacco, the excised shoots were stained with the GUS 
histochemical reagent. Then, the stained shoots were immersed in 70% ethanol (for 
removing chlorophyll) before fix in FAA solution. 
3.2.8.2 DNA extraction
The genomic DNA of inoculated banana cell suspensions and transgenic tobacco 
leaves was isolated using DNeasy plant mini kit (Qiagen). The experiment was carried 
out based on the provided protocol and buffers.
Firstly, 100mg of inoculated banana cell suspensions were ground into fine 
powder by using mortar and pestle with liquid nitrogen. Then, the samples were 
transferred into the 1.5ml microcentrifuge tubes which contained 400µl AP1 buffer with 
4µl 100mg/ml RNase A. The mixture was vortex vigorously before incubate at 65ºC for 
10 minutes. After that, 150µl AP2 buffer were added and incubated on ice for 5 minutes 
to precipitate the detergents, proteins and polysaccharide. Then, the lysate was 
centrifuged at 14000rpm for 5 minutes. The lysate was pipetted into the QIAshredder 
mini spin column and centrifuged at 14000rpm for 2 minutes. The flow-through fraction 
was transferred into a 1.5ml microcentrifuge tube and 1.5 volumes of AP3/E buffer 
were added and mixed by pipetting.
Then, the mixture was transferred into the DNeasy mini spin column and 
centrifuged at 8000rpm for 1 minute. After centrifugation, the DNeasy mini spin 
column was transferred to a new 2.0ml collection tube and 500µl AW buffer were 
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added and centrifuged at 8000rpm for 1 minute. The flow-through was discarded and 
another 500µl AW buffer were added before centrifuge at 14000rpm for 2 minutes.
Finally, 50µl AE buffer were added directly onto the membrane and incubated at 
room temperature for 5 minutes before centrifugation at 8000rpm for 1 minute. The 
isolated genomic DNA were electrophoresed on agarose gel (referred to Appendix A10 
(i)) before stored at -20ºC.
3.2.8.3 PCR
The isolated genomic DNA of inoculated banana cell suspensions and transgenic 
tobacco was used as template for PCR analysis. 
For genomic DNA of inoculated banana cell suspensions, 2 sets of primers, 
1304SK_F & 1304SK_R and NtAct_F&NtAct_R (referred to Table 3.4) were used to 
analysis. Whilst, 1304SK_F & 1304SK_R and Actin9_F & Actin9_R (referred to Table 
3.4) were used to analyze transgenic tobacco. 
Thermal cycle conditions were set as described in Table 3.1. The PCR products 
were electrophoresed on agarose gel (referred to Appendix A10(i)).
3.2.9 Verification of transgenic plant via Real-Time PCR analysis
3.2.9.1 RNA extraction
The RNA of transgenic tobacco was isolated using easy-spinTM [DNA free] Total 
RNA Extraction Kit which purchased from iNtRON Biotechnology. The RNA was 
isolated based on the provided protocol and buffers.
Firstly, 100mg of fresh transgenic tobacco leaves was ground into fine powder 
using mortar and pestle with liquid nitrogen. The ground tissue sample was transferred 
into 1.5ml microcentrifuge tube which contained 1ml lysis buffer (easy-BLUETM
reagent) and vortexed vigorously at room temperature for 10seconds. Then, 200µl of 
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chloroform were added and vortexed. The mixture was centrifuged at 4ºC with 
13000rpm for 10 minutes. 
After centrifugation, 400µl of upper fluid were transferred into 1.5ml 
microcentrifuge tube. Then, 400µl of binding buffer were added and mixed by pipetting. 
The mixture was loaded into spin column and centrifuged at 13000rpm for 30 seconds. 
The flow-through was discarded and 700µl of washing buffer A was added. Again, the 
tube was centrifuge at 13000rpm for 30 seconds.  Then, 700µl of washing buffer B was 
added and centrifuged at 13000rpm for 30 seconds. The flow-through was discarded 
and the spin column was placed back to the collection tube; and centrifuged at 
13000rpm for 2 minutes to dry the membrane.
Lastly, the spin column was placed into a 1.5ml microcentrifuge tube and 50µl of 
elution buffer were added to the membrane. Then, the membrane was incubated at room 
temperature for 1 minute before centrifuge at 13000rpm for 1 minute. Then, the elution 
products were performed with agarose gel electrophoresis (referred to Appendix A10 
(ii)).
OD 260/280 assay also carry out to determine the RNA concentration of the samples. 
For pure RNA, the ratio of absorbance, A260/280, should be in the range of 1.8-2.0; 
however, the range of 1.7-2.0 was considered sufficient purity. For measuring RNA 
concentration, 2µl of samples were mixed with 98µl DEPC-treated distilled H2O. The 
diluted samples were measured at wavelength of 260nm and 280nm. The readings were 
taken against a blank of 100µl DEPC treated distilled H2O.
After measuring the RNA concentration, DNase I (Invitrogen) treatment was 
carried out on the RNA samples for removing the remaining DNA. The reaction mixture 
was prepared as showed in the Table 3.11.
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Table 3.11: DNaseI treatment reaction mixture.
Component Working concentration Volume, µl
RNA sample 1µg Concentration dependent
10x DNaseI reaction buffer 1x 1
DNaseI (1U/µl) 1U 1
DEPC-treated H2O to - 10µl
The tube with reaction mixture was mixed and incubated at room temperature for 15 
minutes. Then, the reaction was inactivated with 1µl of 25mM EDTA solution and 
heated at 65ºC for 10minutes. Then, agarose gel electrophoresis (referred to Appendix 
A10 (ii)) was carried out on the treated RNA samples.
3.2.9.2 Reverse-transcriptase PCR
The Reverse-transcriptase PCR was carried out using high-capacity cDNA reverse 
transcriptase kit that purchased from Applied Biosystems.
The reaction mixture was prepared as stated in Table A2 (Appendix A4b).Then, 
10µl of reaction mixtures were aliquoted into ice-cold 0.2ml PCR tubes; 10µl of DNaseI 
treated RNA were added and mixed by pipetting up and down. Then, the tubes were 
centrifuged briefly before loaded into PCR machine. The thermal cycling condition of 
Reverse-transcriptase PCR was mentioned as below;
25 ºC 10 minutes
37 ºC 120 minutes 
85 ºC 5 minutes
4ºC ∞
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3.2.9.3 Real-time PCR
The quantitative PCR was carried out using Applied Biosystems 7500 Real-time 
PCR System.
Firstly, the examination of primer set (referred to Table 3.5) specificity were 
performed with dissociation program. The primer set with single peak indicates the 
higher specificity of primer. The reaction mixtures were prepared as mentioned in Table 
A3 (Appendix A4c). Four replicates of each primer set and a negative control (without 
cDNA template) were prepared and assayed with the following dissociation program;
30 cycles 95 ºC for 15seconds 
1 cycle 60 ºC for 1minutes 
1 cycle 95 ºC for 15seconds
After examining the primer specificity, a relative standard curve with 5x serial 
dilution of cDNA was constructed. Five series of 5x serial dilution of cDNA was carried 
out and used as template for performing Relative Quantification PCR. The Real-Time 
PCR reaction mixture (referred to Table A3 in Appendix A4c) with 3 set primers (as 
showed in Table 3.5) were prepared. Four replicates of each serial dilution and a 
negative control (without cDNA template) were used in the experiment. The thermal 
cycling condition for Relative Quantification PCR, as below:
Stage 1 95 ºC for 10 minutes 1cycle
Stage 2 95 ºC for 1minutes 
60 ºC for 15seconds
Then, the collected data was performed with Relative Quantification Study using 
SDS Software 1.3.1 to generate the Ct value. A standard curve was plotted with the log 
input amount versus Ct value. 
After obtaining the relative standard curve, the relative quantification of gene 
expression was carried out on cDNA of transgenic tobacco with pCambia1304 vector 
40 cycles
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(as plant expression vector control) and cDNA of transgenic tobacco with 
pToxo130BBIKDEL and pToxo130BBI. The cDNA of non-transformed tobacco was 
used as control for the experiment. Four replicates and a negative control (without 
cDNA template) were prepared for each sample. The thermal cycling condition for 
Relative Quantification PCR, as mentioned above was used to quantitate the gene 
expression.
All data of Relative Quantification plates were used to perform the Relative 
Quantification Study (SDS Software 1.3.1) for comparing the gene expression level in 
between transgenic tobacco pToxo130BBIKDEL and pToxo130BBI with non-
transformed tobacco.
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3.2.10 Flow chart of study
Figure 3.6: Flow chart used in developing the constructs (pToxo64BBI and
pToxo64BBIKDEL).
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Figure 3.7: Flow chart for the development of the constructs (pToxo130BBI and
pToxo130BBIKDEL).
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Figure 3.8: Flow chart for Agrobacterium-mediated transformation into banana cell
suspensions.
pToxo64BBI, 
pToxo64BBIKDEL, 
pToxo130BBI & 
pToxo130BBIKDEL
Transformation
PCR Screening
Inoculation 
Overnight, shaking
Infection, 30 min, 
dark, shaking
Co-cultivation, 
3 days, dark
Agrobacterium competent 
cells preparation
Sieve the cells through 
425µM-mesh
Maintaining of banana cell 
suspensions
Agrobacterium 
Elimination 
Incubation 
Genomic DNA 
isolation 
Selection& 
Regeneration
PCR Analysis 
GUS Histochemical 
staining
48
Figure 3.9: Flow chart for Agrobacterium-mediated transformation into tobacco leaf
discs.
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CHAPTER 4: RESULTS
4.1 Preparation of vectors and inserts
4.1.1 pCambia1304 and pCambia1304AvrII
The glycerol stock of the E.coli strain JM109 harbouring the plant transformation 
vector pCambia1304 and the E.coli strain JM109 harbouring pCambia1304AvrII were 
successfully cultured and the plasmids extracted. The isolated plasmids are as shown in 
Figure 4.1. The ODA260/280 readings of the extracted plasmids are shown in Table 4.1 
and 4.2 respectively indicating concentrations attained between 1.4 to 2.4µg/µl with 
sufficient purity for the subsequent procedures.
(a)
(b)
Figure 4.2:  Agarose gel electrophoresis of pCambia vectors.
(a) pCambia1304 in the 1% EtBr-stained agarose gel
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-15: pCambia1304 from plasmid extraction.
(b) pCambia1304AvrII in the 1% EtBr-stained agarose gel
Lane 1-10: pCambia1304AvrII from plasmid extraction.
Lane 11: Marker; 1kb DNA ladder (EURX).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1 2 3 4 5 6 7 8 9 10 11
1kb
2kb
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Table 4.1: Concentration of pCambia1304.
Table 4.2: Concentration of pCambia1304AvrII.
Sample Concentration µg/µl Purification Sample
Concentration 
µg/µl Purification
1 1.166 1.81 6 1.591 1.81
2 1.266 1.81 7 1.635 1.80
3 2.765 1.83 8 1.431 1.80
4 1.128 1.81 9 1.313 1.80
5 0.987 1.78 10 1.323 1.81
Sample Concentrationµg/µl Purification Sample
Concentration 
µg/µl Purification
1 2.622 1.87 8 2.401 1.92
2 3.137 1.88 9 1.886 1.91
3 2.962 1.91 10 1.769 1.90
4 1.821 1.91 11 2.513 1.88
5 3.045 1.90 12 1.787 1.90
6 1.984 1.89 13 1.681 1.89
7 1.682 1.87 14 1.584 1.91
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4.1.2 scFv64 and scFv130 antibody fragments
As described in Section 3.1, PCR screening was carried out to select the 
appropriate E.coli colony harbouring the scFv64 and scFv130 antibody fragments. Ten 
colonies for each clone were randomly selected. All colonies selected potentially 
harbouring the scFv130 antibody fragment showed positive results; while for scFv64 
antibody fragment clone only 9 colonies gave positive amplification. The expected size 
of the PCR products for both fragments was approximately 850bp, as shown in Figure 
4.2. 
Seven colonies giving positive amplification for each of the clones (scFv64 and 
scFv130) were subcultured prior to plasmid extraction. The plasmids of scFv64 and 
scFv130 antibody fragments were successfully extracted from the E. coli, as shown in 
Figure 4.3. The concentration based on  ODA260/280 results of the plasmid extracts are 
listed in Table 4.3.
A pairs of specific primers were designed for both clones (scFv64NcoI_F and 
scFvHindIII_R for scFv64; scFv130AvrII_F and scFvHindIII_R for scFv130) with 
some modifications or additions of nucleotides inserted into the primers to generate new 
restriction sites for ease of cloning. The amplification resulted in the addition of new 
terminal restriction enzyme sites, NcoI and HindIII, for scFv64 antibody fragment and 
AvrII and HindIII for the scFv130 antibody fragment. Gradient PCR was carried out to 
determine the optimal annealing temperature for both clones, as shown in Figure 4.4. 
The fragments were successful amplified at 42ºC and the expected size for both 
amplicon was approximately 800bp, as shown in Figure 4.5.
After PCR amplification, the products (scFv64 and scFv130 antibody fragments 
with the desired restriction enzyme sites) were purified using QIAquick PCR 
Purification Kit. The sizes of the scFv64 and scFv130 antibody fragments after 
purification were both approximately 800bp, as shown in Figure 4.6.
52
Figure 4.2: PCR screening for scFv64 and scFv130 antibody fragments using 
pCANTAB 5E_S1 and pCANTAB 5E_S6 primers.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2: Negative control; without DNA template.
Lane 3-12: Colonies of scFv130 antibody fragment clone.
Lane 13-22: Colonies of scFv64 antibody fragment clone.
Figure 4.3:  Agarose gel electrophoresis of plasmids with scFv130 and scFv64 
antibody fragment after extraction. 
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-8: Plasmid of scFv130 antibody fragment obtained from 
pCANTAB5E.
Lane 9-15: Plasmid of scFv64 antibody fragment obtained from 
pCANTAB5E.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
~850bp1kb
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1kb
500bp
scFv130 scFv64
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Table 4.3: Concentration of scFv64 and scFv130 antibody fragments.
Figure 4.4: PCR optimization of scFv64 and scFv130 antibody fragments.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1-8: Amplicon of scFv64 antibody fragment using 
scFv64NcoI_F & scFvHindIII_R with gradient annealing
temperatures (42.0 ºC -58.0ºC).
Lane 9: Marker; 100bp DNA ladder (EURX).
Lane 10-11: Amplicon of scFv130 antibody fragment using 
scFv130AvrII_F & scFvHindIII_R with gradient annealing
temperatures (42.0ºC-58.0ºC).
scFv130 antibody fragment scFv64 antibody fragment
Sample Concentration µg/µl Purification Sample
Concentration 
µg/µl Purification
1 2.473 1.90 8 2.562 1.88
2 2.230 1.85 9 2.765 1.87
3 2.451 1.85 10 2.599 1.83
4 2.167 1.86 11 2.007 1.87
5 2.353 1.89 12 2.606 1.84
6 2.687 1.88 13 2.214 1.78
7 2.851 1.84 14 2.751 1.85
~800bp
500bp
1kb
11 12 13 14 15 16 171 2 3 4 5 6 7 8 9 10
scFv64 scFv130
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Figure 4.5: PCR amplification with optimum annealing temperature, 42°C.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1 & 6: Negative control, without DNA template.
Lane 2-4: Amplicon of the scFv64 antibody fragment using
scFv64NcoI_F & scFvHindIII_R.
Lane 5: Marker; 100bp DNA ladder (EURX).
Lane 7-9: Amplicon of the scFv130 antibody fragment using
scFv130AvrII_F & scFvHindIII_R.
Figure 4.6: PCR purification products of scFv64 and scFv130 antibody fragments.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1-3: Purification PCR products of scFv64 antibody fragment
with NcoI and HindIII.
Lane 4: Marker; 100bp DNA ladder (EURX).
Lane 5-7: Purification PCR products of scFv130 antibody fragment 
with AvrII and HindIII.
1 2 3 4 5 6 7 8 9
500bp
~800bp
1 2 3 4 5 6 7
500bp
~800bp
1kb
1kb
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4.1.3 Amplification of BBIKDEL and BBI gene fragments
PCR optimization was carried out using a synthetic BBIKDEL gene fragment as a 
template with 57BBIKDEL_F (forward) and 57BBIKDEL_R (reverse) primers.  
Gradient annealing temperatures, 50.0ºC (Lane2), 50.8ºC (Lane3),  52.1ºC (Lane4),  
54.0ºC (Lane5),  56.2ºC (Lane6),  58.0 ºC (Lane7),  59.3 ºC (Lane8), and 60.0 ºC 
(Lane9) were used in the optimisation of the PCR. The expected size of the amplicon 
was approximately 800bp (Figure 4.7). The optimum annealing temperature was found 
to be at 59.3ºC, as shown in Figure 4.7.
The plasmid harbouring the synthetic BBIKDEL gene fragment was transformed 
into E.coli JM109 strain. PCR screening was carried out with a 57BBIKDEL primer set 
to screen for the positive colony. The expected amplicon (~800bp) from the PCR 
screening is as shown in Figure 4.8. Out of 22 colonies, 21 colonies gave a positive 
result (Figure 4.8).
The screened colonies with positive result were inoculated into LB broth prior to 
plasmid extraction. The extracted plasmids were electrophoresed on 1% agarose gel, as 
shown in Figure 4.9. The ODA260/280 readings of the extracted plasmid are as given in 
Table 4.4.
PCR amplification with the specific primers (57BBIKDEL_F and 57BBI_R for 
amplifying the BBIKDEL gene fragment; and 57BBI_F and 57BBI_R for amplifying 
the BBI gene fragment) was carried out.  The expected size for both amplicon, for, 
BBIKDEL and BBI gene fragment, were approximately 800bp (as shown in Figure 
4.10).
Then, the PCR products were purified using QIAquick PCR Purification kit. The 
size of the purified BBIKDEL and BBI gene fragments were as expected at 
approximately ~800bp, as shown in Figure 4.11. 
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Figure 4.7: PCR optimisation for amplification of BBIKDEL gene fragment with 
57BBIKDEL_F and 57BBIKDEL_R primer.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2: BBIKDEL gene fragment at different annealing
temperature (Lane 2:50.0ºC; Lane 3: 50.8ºC; Lane 4:
52.1ºC; Lane 5: 54.0ºC; Lane 6: 56.2ºC; Lane 7: 58.0ºC; 
Lane 8:59.3ºC; Lane 9: 60.0ºC).
Lane 10: Negative control; without DNA template.
Figure 4.8: PCR screening of BBIKDEL gene fragment.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1:          Marker; 100bp DNA ladder (EURX).
Lane 2: Negative control; without DNA template.
Lane 3: Positive control; plasmids harbouring the BBIKDEL gene
fragment.
Lane 4- 25:   Colonies selected from the agar plate.
Figure 4.9: Plasmids harbouring the BBIKDEL gene fragment.
The samples were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-17: Purified plasmids with the BBIKDEL gene fragment.
1 2 3 4 5 6 7 8 9 10
500bp
~800bp
500bp
~800bp
171 2 3 4 5 6 7 8 9 10 11 12 1314 15 16 18 19 20 21 22 23 24 25
1kb
1kb
1kb
1 2 3 4 5 6 7 8 9 1110 12 13 14 15 16 17
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Table 4.4: Concentration of BBIKDEL gene fragment.
Figure 4.10: PCR amplification for BBIKDEL and BBI gene fragments.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1 & 5: Negative control; without DNA template.
Lane 2-3: BBIKDEL gene fragment with desired RE sites.
Lane 4:  Marker; 100bp DNA ladder (EURX).
Lane 6-7: BBI gene fragment with the desired RE sites.
Figure 4.11: PCR purification product of BBIKDEL and BBI gene fragments.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1-2: Purification PCR products of BBI gene fragment.
Lane 3: Marker; 100bp DNA ladder (EURX).
Lane 4-5: Purification PCR products of BBI KDEL gene fragment.
Sample Concentration µg/µl Purification Sample
Concentration 
µg/µl Purification
1 1.285 1.83 9 1.546 1.81
2 1.705 1.85 10 1.644 1.78
3 1.629 1.79 11 1.835 1.81
4 1.124 1.74 12 1.662 1.81
5 1.394 1.75 13 1.570 1.82
6 0.274 1.77 14 1.637 1.81
7 1.361 1.80 15 1.563 1.79
8 1.486 1.83 16 1.228 1.78
~800bp
1 2 3 4 5 6 7
500bp
1 2 3 4 5
~800bp1kb
500bp
1kb
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4.2 Restriction enzyme digestion
4.2.1 Digestion of pCambia1304 and pCambia1304AvrII
pCambia1304 was digested with NcoI and BglII, while the pCambia1304AvrII 
was digested with AvrII and BglII. The digestion products were electrophoresed on 1% 
EtBr-stained electrophoresis gel, as shown in Figure 4.12.
(a)  (b)
Figure 4.12: Restriction enzyme digestion of vector with NcoI and BglII enzymes. 
The products were electrophoresed on 1% EtBr-stained agarose gel.
(a) pCambia1304
Lane 1:   Marker; 1kb DNA ladder (EURX).
Lane 2:   Undigested pCambia1304, as control.
Lane 3-4:   pCambia1304 digested with NcoI and BglII (expected size: 
~12kb).
(b) pCambia1304AvrII
Lane 1:   Marker; 1kb DNA ladder (EURX).
Lane 2 & 4:   Undigested pCambia1304 AvrII, as control.
Lane 3 & 5:   pCambia1304AvrII digested with AvrII and BglII 
(expected size: ~12kb).
1 2 3 4 1 2 3 4 5
1kb
~12kb ~12kb
1kb
59
4.2.2 Digestion of scFv64 & scFv130 antibody fragments and
BBIKDEL & BBI gene fragments
PCR products of scFv64 antibody fragment were digested using NcoI and HindIII, 
and scFv130 antibody fragment with AvrII and HindIII. Enzymes that was used to 
digest PCR products of BBIKDEL and BBI gene fragments were HindIII and BglII. The 
digestion products were electrophoresed on 1% EtBr-stained agarose gel with un-
digested PCR products as a control.
The digestion product sizes of scFv64 and scFv130 antibody fragments were 
approximately 800bp, while BBIKDEL & BBI gene fragments were approximately 
650bp (as shown in Figure 4.13).
Figure 4.13: Restriction enzyme digestion of scFv64 & scFv130 antibody fragments 
and BBIKDEL & BBI gene fragments using different restriction enzymes. 
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1:   Undigested scFv64 antibody fragment, ~800bp.
Lane 2:   scFv64 antibody fragment digested with NcoI and HindIII, 
~800bp.
Lane 3:   Undigested scFv130 antibody fragment, ~800bp.
Lane 4:  scFv130 antibody fragment digested with AvrII and 
HindIII, ~800bp.
Lane 5:   Undigested BBIKDEL gene fragment, ~800bp.
Lane 6:   BBIKDEL gene fragment digested with HindIII and BglII, 
~650bp.
Lane 7: Undigested BBI gene fragment, ~800bp.
Lane8: BBI gene fragment digested with HindIII and BglII, 
~650bp.
Lane 9:   Marker; 100bp DNA ladder (EURX).
1 2 3 4 5 6 7 8 9
~650bp
~800bp 1kb
500bp
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4.2.3 Purification of digested pCambia1304 and pCambia1304AvrII 
Digestion products of pCambia1304 and pCambia1304AvrII were purified using 
QIAquick Gel Extraction Kit. The purified digested pCambia1304 and 
pCambia1304AvrII were electrophoresed on agarose gel, as shown in Figure 4.14.
Figure 4.14: Gel purification product of digested pCambia1304 and 
pCambia1304AvrII.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1:   Purification of digested pCambia1304, ~12kb.
Lane 2-3:   Purification of digested of pCambia1304AvrII, ~12kb.
Lane 4: Marker; 1kb DNA ladder (EURX).
1 2 3 4
1kb
~12kb
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4.2.4 Purification of digested scFv64 & scFv130 antibody fragments and
BBIKDEL & BBI gene fragments
Follow 4.2.3, the products were electrophoresed on agarose gel and result was 
showed in Figure 4.15. Expected size of digested scFv64 and scFv130 antibody 
fragments are approximately 800bp; while BBIKDEL and BBI gene fragment are 
approximately 650bp.
Figure 4.15: Gel purification products of digested scFv64 and scFv130 antibody 
fragments and BBIKDEL & BBI gene fragments.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1-2: Purified digested product of scFv64 fragment, ~800bp.
Lane 3-4: Purified digested product of scFv130 fragment, ~800bp.
Lane 5: Marker; 100bp DNA ladder (EURX).
Lane 6-7: Purified digested product of BBIKDEL gene fragment, 
~650bp.
Lane 8-9: Purified digested product of BBI gene fragment, ~650bp.
1 2 3 4 5 6 7 8 9
1kb
500bp
~800bp
~650bp
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4.3 Cloning and transformation into E.coli
4.3.1 Construction of pToxo64BBI, pToxo64BBIKDEL, pToxo130BBI and 
pToxo130BBIKDEL
The purified digestion products of pCambia1304 and pCambia1304AvrII with 
scFv64, scFv130, BBI and BBIKDEL were ligated together, as summarized in Table 
4.5. The constructs were then transformed into E.coli JM109 competent cells. 
Table 4.5: Combination of vector and inserts for 4 different constructs.
Construct Vector Insert
pToxo64BBI pCambia1304 scFv64 and BBI
pToxo64BBIKDEL pCambia1304 scFv64 and BBIKDEL
pToxo130BBI pCambia1304AvrII scFv130 and BBI
pToxo130BBIKDEL pCambia1304AvrII scFv130 and BBIKDEL
4.3.2 Colony selection and PCR analysis
Colony PCR was carried out for confirmation. The colonies were screened with 
1304SK_F and 1304SK_R primers. The expected size of amplicon is approximately 
1.5kb, as shown in Figure 4.16.
For pToxo64BBI and pToxo64BBIKDEL, 5 colonies of each construct have been 
selected randomly to analyse with PCR using 1304SK primers. Out of 5 colonies that 
were selected, only one colony gave a positive result for each construct (refer to Lane 6 
and Lane 9 of Figured 4.16a). While, for pToxo130BBI and pToxo130BBIKDEL, out 
of 6 randomly selected colonies, only one colony of each construct gave positive result 
for each construct (refer to Lane 3 and Lane 12 of Figure 4.16b). 
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(a)
(b)
Figure 4.16: PCR screening of E.coli colonies with 1304SK primers.
The products were electrophoresed on 1% EtBr-stained agarose gel.
(a) pToxo64BBI and pToxo64BBIKDEL
Lane 1: Negative control; without DNA template.
Lane 2-6: Colony PCR of  pToxo64BBI.
Lane 7: Marker; 100bp DNA ladder (EURX).
Lane 8-12: Colony PCR of  pToxo64BBIKDEL.
(b) pToxo130BBI and pToxo130BBI-KDEL
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2-7: Colony PCR of pToxo130BBI.
Lane 8-12: Colony PCR of pToxo130BBIKDEL.
Lane 13: Negative control; without DNA template.
1 2 3 4 5 6 7 8 9 10 11 12
1kb
500bp
~1.5kb
500bp
~1.5kb
1 2 3 4 5 6 7 8 9 10 11 12 13
1kb
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4.3.3 Plasmid extraction of the constructs (pToxo64BBI, pToxo64BBIKDEL, 
pToxo130BBI and pToxo130BBIKDEL)
The positive colony (from Section 4.3.2) was inoculated in LB broth and plasmid 
extraction was carried out. Bacterial culture was prepared in duplicates for each 
construct prior to plasmid extraction. The extracted plasmids were electrophoresed on 
agarose gel (as shown in Figure 4.17) and ODA260/280 readings are as listed in Table 4.6.
Figure 4.17: Plasmid extraction from E.coli JM109 harbouring different constructs.
The samples were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-3: pToxo64BBI.
Lane 4-5: pToxo64BBIKDEL.
Lane 6-7: pToxo130BBI.
Lane 8-9: pToxo130BBIKDEL.
Table 4.6: Concentration of plasmids for all constructs after extraction.
Sample Construct Concentration µg/µl Purification
1 pToxo64BBI 1.789 1.84
2 pToxo64BBI 1.381 1.81
3 pToxo64BBIKDEL 1.189 1.81
4 pToxo64BBIKDEL 0.914 1.81
5 pToxo130BBI 1.063 1.80
6 pToxo130BBI 1.076 1.78
7 pToxo130BBIKDEL 1.607 1.81
8 pToxo130BBIKDEL 1.627 1.81
21 3 4 5 6 7 8 9
1kb
65
4.3.4 PCR confirmation
PCR confirmation was carried out for all constructs (i.e. pToxo64BBI, 
pToxo64BBIKDL, pToxo130BBI and pToxo130BBIKDEL) with 1304SK primers. All 
constructs showed positive results (~1.5kb), as shown in Figure 4.18. Purified PCR 
products were sent for sequencing for further verification.
Figure 4.18: PCR confirmation for all constructs using 1304SK primers. 
The products were electrophoresed on 1% EtBr-stained agarose gel 
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2: Negative control; without DNA template.
Lane 3-4: PCR product of pToxo64BBI.
Lane 5-6: PCR product of pToxo64BBIKDEL.
Lane 7-8: PCR product of pToxo130BBI.
Lane 9-10: PCR product of pToxo130BBIKDEL.
21 3 4 5 6 7 8 9 10
~1.5kb
500bp
1kb
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4.3.5 Restriction enzyme digestion for all constructs
All constructs (pToxo64BBI, pToxo64BBIKDEL, pToxo130BBI and 
pToxo130BBIKDEL) were digested with NdeI to examine the integration of the desired 
gene. The sizes of the digested fragments of each construct are as shown in Table 4.7. 
The digestion products were electrophoresed on 1% EtBr-stained agarose gel, as shown 
in Figure 4.19.
Table 4.7: Fragment sizes after digestion with NdeI.
Construct Expected size of fragment after digestion with NdeI, bp
pCambia1304 4283 3020 2569 2489
pToxo64BBI 4283 3020 3974 2489
pToxo64BBIKDEL 4283 3020 3995 2489
pToxo130BBI 4283 3020 3977 2489
pToxo130BBIKDEL 4283 3020 3998 2489
Figure 4.19: Digestion products for all constructs with NdeI.
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2: Digestion product of pCambia1304, size:2569bp.
Lane 3: Digestion product of pToxo64BBI, size:3974bp.
Lane 4: Digestion product of pToxo64BBIKDEL, size:3995bp.
Lane 5: Digestion product of pToxo130BBI, size:3977bp.
Lane 6: Digestion product of pToxo130BBIKDEL, size:3998bp.
1 2 3 4 5 6 The transgene 
(~1.5kb) was 
ligated into this 
fragment.
1kb
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4.3.6 Sequencing
The sequencing results confirmed the correct sequences for all constructs 
(pToxo64BBI, pToxo64BBIKDEL, pToxo130BBI and pToxo130BBIKDEL). The 
sequencing results are attached in Appendix C.
4.4 Cloning and transformation into Agrobacterium sp.
4.4.1 PCR screening on Agrobacterium sp. colony after transformation
The four constructs (pToxo64BBI, pToxo64BBIKDEL, pToxo130BBI and 
pToxo130BBIKDEL) were transformed into Agrobacterium sp. strain LBA4404 
competent cells. Few colonies were seen on the LB agar plates. Five colonies of each 
construct were selected randomly and analysed with 1304SK primers and gfp primers.  
All selected colonies showed positive results, as shown in Figure 4.20.
pCambia1304 without transgene was also transformed into Agrobacterium sp. 
strain LBA4404 as a control. Two colonies were picked randomly and analyzed with 
gfp primers. Both colonies showed positive results, amplifying an approximately 750bp 
band (Lane 1 and Lane 2 in Figure 4.20b).
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(a)
(b)
Figure 4.20: PCR screening for Agrobacterium sp. colonies after transformation.
The products were electrophoresed on 1% EtBr-stained agarose gel.
(a) Analysis with 1304SK primers
Lane 1-5: Colonies of Agrobacterium sp. harboured pToxo64BBI.
Lane 6-10: Colonies of  Agrobacterium sp. harboured 
pToxo64BBIKDEL.
Lane 11: Marker; 100bp DNA ladder (EURX).
Lane 12-16: Colonies of  Agrobacterium sp. harboured pToxo130BBI.
Lane 17-21: Colonies of  Agrobacterium sp. harboured 
pToxo130BBIKDEL.
Lane 22: Negative control; without DNA template.
Lane 23: Positive control; plasmid of construct (pToxo130BBI).
(b) Analysis with gfp primers
Lane 1-2: Colonies of Agrobacterium sp. harboured pCambia1304.
Lane 3-7: Colonies of Agrobacterium sp. harboured pToxo64BBI.
Lane 8-12: Colonies of Agrobacterium sp. harboured 
pToxo64BBIKDEL.
Lane 13: Marker; 100bp DNA ladder (EURX).
Lane 14-18: Colonies of Agrobacterium sp. harboured pToxo130BBI.
Lane 19-23: Colonies of Agrobacterium sp. harboured 
pToxo130BBIKDEL.
Lane 24: Negative control; without DNA template.
Lane 25: Positive control; plasmid of construct (pToxo130BBI).
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4.5 Agrobacterium-mediated transformation into banana cell suspensions
4.5.1 GUS histochemical staining on inoculated cell suspensions
GUS assay was carried out on selected cell suspensions (after 4 days co-
cultivation with the Agrobacterium sp. harbouring transgenes) as a transient assay prior 
to transformation. The non-inoculated cell suspensions were prepared as negative 
controls of the experiment. 
As shown in Figure 4.21a, no blue colour spot was observed on the non-
inoculated cell suspensions. The inoculated cell suspensions gave positive result, where 
blue colour spots were observed, as shown in Figure 4.21b-f. The stained cell 
suspensions were visualized under contrast phase light microscope with 400x 
magnification (refer to Figure 4.22). 
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Figure 4.21: GUS histochemical staining of inoculated banana cell suspensions after 4 
days co-cultivation with  Agrobacterium sp.
Figure a: Non-inoculated; as negative control.
Figure b: Inoculated with pCambia1304, as positive control.
Figure c: Inoculated with  Agrobacterium sp. harboured 
pToxo64BBI.
Figure d: Inoculated with Agrobacterium sp. harboured 
pToxo64BBIKDEL.
Figure e: Inoculated with Agrobacterium sp. harboured 
pToxo130BBI.
Figure f: Inoculated with Agrobacterium sp. harboured 
pToxo130BBIKDEL.
Figure 4.22: Microscopic visualization of non-inoculated and inoculated banana cell 
suspensions after GUS histochemical staining.
Figure a: Non-inoculated banana cell suspensions; as negative 
control (400x magnification).
Figure b: Inoculated banana cell suspensions (400x magnification).
Blue spots were observed on the inoculated cells.
Blue spot on 
inoculated cell 
suspensions
(a) (c)(b)
(f)(e)(d)
(b)
400x Magnification400x Magnification
(a)
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4.5.2 Molecular analysis of inoculated banana cell suspensions
4.5.2.1 Genomic DNA isolation of inoculated banana cell suspensions
Genomic DNA of inoculated banana cell suspensions was isolated after co-
cultivation with Agrobacterium sp. elimination media for one month. The genomic 
DNA was electrophoresed on 1% EtBr-stained agarose gel, as shown in Figure 4.23. 
The isolated genomic DNA was used as template in PCR analysis.
Figure 4.23: Genomic DNA of inoculated banana cell suspensions after 1 month co-
cultivation with Agrobacterium sp. elimination media.
The samples were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-3: Genomic DNA of non-transformed cell suspensions.
Lane 4-8: Genomic DNA of  pCambia1304 inoculated cell 
suspensions.
Lane 9-13: Genomic DNA of pToxo130BBI inoculated cell 
suspensions.
Lane 14-17: Genomic DNA of pToxo130BBIKDEL inoculated cell
suspensions.
Lane 18-20: Genomic DNA of pToxo64BBI inoculated cell 
suspensions.
Lane 21-23: Genomic DNA of pToxo64BBIKDEL inoculated cell
suspensions.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2221 23
1kb
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4.5.2.2 PCR analysis of genomic DNA of inoculated banana cell 
suspensions
PCR was carried out on the isolated genomic DNA. As shown in Figure 4.24, all 
samples showed positive results (amplification of an approximately 400bp band) when 
examined with the NtAct_F and NtAct_R primers. Thus, the genomic DNA of banana 
has been successfully isolated from the cell. 
The presence of transgene in the genomic DNA was verified by PCR with 
1304SK primers. Unfortunately, no positive results were observed in all the specimens 
tested.
Figure 4.24: PCR analysis for the isolated genomic DNA with actin (NtAct) primers. 
The products were electrophoresed on 1% EtBr-stained agarose gel.
Lane 1-2: PCR product of non-transformed cell suspensions.
Lane 3-7: PCR product of  pCambia1304 inoculated cell 
suspensions.
Lane 8-12: PCR product of pToxo130BBI inoculated cell 
suspensions.
Lane 13: Marker; 1kb DNA ladder (EURX).
Lane 14-17: PCR product of pToxo130BBIKDEL inoculated cell 
suspensions.
Lane 18-20: PCR product of  pToxo64BBI inoculated cell suspensions.
Lane 21-23: PCR product of  pToxo64BBIKDEL inoculated cell 
suspensions.
Lane 24: Negative control; without DNA template.
~400bp500bp
b
1kb
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2221 23 24
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4.6 Agrobacterium-mediated transformation into tobacco leaf discs
4.6.1 GUS histochemical staining on regenerated tobacco plantlets
The one month old regenerated plantlets were stained with GUS histochemical 
reagents. In total 2 controls and 2 samples were analysed. The plant vector control and 2 
transgenic plantlets both exhibited blue colouration after staining; while no colour 
changes were seen on non-transgenic plantlets. The results are as shown in Figure 4.25. 
Figure 4.25: GUS histochemical staining of one month old non-transformed tobacco 
and transgenic tobacco plantlets.
Figure a: Non-transformed tobacco; as negative control.
Figure b: Transgenic tobacco plantlet with pCambia1304; as plant 
vector control.
Figure c: Transgenic tobacco plantlet with pToxo130BBI.
Figure d: Transgenic tobacco plantlet with pToxo130BBIKDEL.
(a) (b) (c) (d)
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4.6.2 Molecular analysis of transgenic tobacco plantlets
4.6.2.1 Genomic DNA isolation of transgenic tobacco leaves
Genomic DNA of 6 month old transgenic tobacco leaves were isolated for further 
verification, as shown in Figure 4.26.
(a)
(b)
(c)
Figure 4.26: Genomic DNA isolation from six month  old plantlets.
The products were analyzed on 1% EtBr-stained agarose gel.
(a) Non-transformed and transgenic tobacco with pCambia1304
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-5: Genomic DNA of non-transformed tobacco leaves.
Lane 6-11: Genomic DNA of transgenic tobacco with pCambia1304.
(b) Transgenic tobacco with pToxo130BBI 
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-21: Genomic DNA of transgenic tobacco with pToxo130BBI.
(c) Transgenic tobacco with pToxo130BBIKDEL
Lane 1: Marker; 1kb DNA ladder (EURX).
Lane 2-21: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
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4.6.2.2  PCR analysis on isolated genomic DNA of transgenic tobacco
As showed in Figure 4.27, the isolated genomic DNAs were analyzed using actin 
gene (Actin9) primers. From the results, all but two of the samples, including non-
transformed and transgenic tobacco, showed positive results.
From the PCR analysis, all except three samples of pToxo130BBI showed 
positive result when examined with 1304SK primers (refer to Lane 2, 4, and 18 in 
Figure 4.28b) and gfp primers (refer to Lane 2, 4, and 18 in Figure 4.29b). For samples 
of pToxo130BBIKDEL, 14 out of 20 samples showed amplification when analysed 
with 1304SK primers and gfp primers, as shown in Figure 4.28c and Figure 4.29c.
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(a)
(b)
(c)
Figure 4.27: PCR analysis for the isolated genomic DNA with Actin9 primers.
The products were analyzed on 1% EtBr-stained agarose gel.
(a) Non-transformed and transgenic tobacco with pCambia1304
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2-5: Genomic DNA of non-transformed tobacco.
Lane 6-11: Genomic DNA of transgenic tobacco with pCambia1304.
Lane 12: Negative control; without DNA template.
(b) Transgenic tobacco with pToxo130BBI
Lane 1 & 14: Marker; 100bp DNA ladder (EURX).
Lane 2-11: Genomic DNA of transgenic tobacco with pToxo130BBI.
Lane 12: Negative control; without DNA template.
Lane 13: Positive control; plasmid of pToxo130BBI.
Lane 15-24: Genomic DNA of transgenic tobacco with pToxo130BBI.
(c) Transgenic tobacco with pToxo130BBIKDEL
Lane 1 &12: Marker; 100bp DNA ladder (EURX).
Lane 2-11: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
Lane 13-22: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
Lane 23: Negative control; without DNA template.
Lane 24: Positive control; plasmid of pToxo130BBI.
1 2 3 4 5 6 7 8 9 10 11 12
~220bp
500bp
1kb
500bp
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(b)
(c)
Figure 4.28: PCR analysis for the isolated genomic DNA with 1304SK primers.
The products were analyzed on 1% EtBr-stained agarose gel.
(a) Non-transformed and transgenic tobacco with pCambia1304
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2-5: Genomic DNA of non-transformed tobacco.
Lane 6-11: Genomic DNA of transgenic tobacco with pCambia1304.
Lane 12: Negative control; without DNA template.
Lane 13: Positive control; plasmid of pToxo130BBI.
(b) Transgenic tobacco with pToxo130BBI
Lane 1 & 12: Marker; 100bp DNA ladder (EURX).
Lane 2-11: Genomic DNA of transgenic tobacco with pToxo130BBI.
Lane 13-22: Genomic DNA of transgenic tobacco with pToxo130BBI.
Lane 23: Negative control; without DNA template.
Lane 24: Positive control; plasmid of pToxo130BBI.
(c) Transgenic tobacco with pToxo130BBIKDEL
Lane 1 & 14: Marker; 100bp DNA ladder (EURX).
Lane 2-11: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
Lane 12: Negative control; without DNA template.
Lane 13: Positive control; plasmid of pToxo130BBI.
Lane 15-24: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
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(c)
Figure 4.29: PCR analysis for the isolated genomic DNA with gfp primers.
The products were analyzed on 1% EtBr-stained agarose gel.
(a) Non-transformed and transgenic tobacco with pCambia1304
Lane 1: Marker; 100bp DNA ladder (EURX).
Lane 2-5: Genomic DNA of non-transformed tobacco.
Lane 6-11: Genomic DNA of transgenic tobacco with pCambia1304.
Lane 12: Negative control; without DNA template.
Lane 13: Positive control; plasmid of pToxo130BBI.
(b) Transgenic tobacco with pToxo130BBI
Lane 1 & 14: Marker; 100bp DNA ladder (EURX).
Lane2-11: Genomic DNA of transgenic tobacco with pToxo130BBI.
Lane 12: Negative control; without DNA template.
Lane 13: Positive control; plasmid of pToxo130BBI.
Lane 15-24: Genomic DNA of transgenic tobacco with pToxo130BBI.
(c) Transgenic tobacco with pToxo130BBIKDEL
Lane 1 & 12: Marker; 100bp DNA ladder (EURX).
Lane 2-11: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
Lane 13-22: Genomic DNA of transgenic tobacco with 
pToxo130BBIKDEL.
Lane 23: Positive control; plasmid of pToxo130BBI.
Lane 24: Negative control; without template.
500bp
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4.7 Real-time PCR analysis
4.7.1 RNA extraction of transgenic tobacco 
After PCR analysis on the isolated genomic DNA of transgenic tobacco, the 
samples which showed positive results were selected for RNA isolation using easy-
spinTM [DNA free] Total RNA Extraction Kit (iNtRON Biotechnology,Inc) prior to 
Real-time PCR.  The isolated RNA was quantified and listed in Table 4.8. The RNA 
isolation products were electrophoresed on 1% EtBr stained agarose gel, as shown in 
Figure 4.30. DNaseI treatment was carried out to remove the remaining genomic DNA 
from 1 µg RNA, as shown in Figure 4.31.
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Table 4.8: ODA260/280 and ODA260/230 readings of non-transformed and transgenic tobacco after RNA extraction.
Sample Concentration µg/µl
Purification
Sample Concentration µg/µl
Purification
ODA260/280 ODA260/230 ODA260/280 ODA260/230
Non-transformed (1) 1.106 1.68 2.51 pToxo130BBI (17) 0.380 1.61 2.07
Non-transformed (2) 1.321 1.71 2.54 pToxo130BBI (19) 0.909 1.74 2.00
pCambia1304 (1) 0.429 1.70 2.25 pToxo130BBI (20) 0.796 1.66 2.35
pCambia1304 (2) 0.463 1.69 2.11 pToxo130BBIKDEL (1) 1.049 1.63 2.35
pToxo130BBI (2) 0.407 1.71 2.11 pToxo130BBIKDEL (2) 1.058 1.67 2.56
pToxo130BBI (4) 2.639 1.79 2.55 pToxo130BBIKDEL (3) 0.863 1.75 2.40
pToxo130BBI (5) 0.744 1.75 1.84 pToxo130BBIKDEL (4) 1.400 1.86 2.33
pToxo130BBI (6) 2.165 1.74 2.66 pToxo130BBIKDEL (5) 0.587 1.67 2.51
pToxo130BBI (7) 0.625 1.70 2.46 pToxo130BBIKDEL (6) 0.471 1.66 2.42
pToxo130BBI (8) 0.658 1.76 1.87 pToxo130BBIKDEL (7) 1.178 1.69 2.60
pToxo130BBI (9) 1.467 1.71 2.56 pToxo130BBIKDEL (9) 0.554 1.75 2.30
pToxo130BBI (10) 1.778 1.73 2.64 pToxo130BBIKDEL (13) 0.982 1.70 2.42
pToxo130BBI (11) 0.600 1.65 2.30 pToxo130BBIKDEL (14) 1.472 1.70 2.56
pToxo130BBI (12) 0.437 1.72 1.76 pToxo130BBIKDEL (16) 0.829 1.61 2.16
pToxo130BBI (13) 0.571 1.65 2.28 pToxo130BBIKDEL (17) 1.217 1.65 2.42
pToxo130BBI (15) 0.529 1.66 2.20 pToxo130BBIKDEL (18) 1.065 1.63 2.39
pToxo130BBI (16) 1.329 1.65 2.53 pToxo130BBIKDEL (19) 1.571 1.71 2.47
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Figure 4.30: RNA of six month old plantlets.
The products were analyzed on 1% EtBr-stained agarose gel.
(a) Non-transformed and transgenic tobacco with pCambia1304
Lane 1-2: RNA of non-transformed tobacco (control).
Lane 3-4: RNA of transgenic tobacco with pCambia1304 vector.
Lane 5: Marker; ssRNA ladder (NEB).
(b) Transgenic tobacco pToxo130BBI
Lane 1: Marker; ssRNA ladder (NEB).
Lane 2-17: RNA of transgenic tobacco pToxo130BBI.
(c) Transgenic tobacco with pToxo130BBIKDEL
Lane 1: Marker; ssRNA ladder (NEB).
Lane 2-15: RNA of transgenic tobacco with pToxo130BBIKDEL.
1 2 3 4 5
3000bp
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Figure 4.31: RNA after removing genomic DNA with DNaseI treatment.
The products were analyzed on 1% EtBr-stained agarose gel.
(a) Non-tansformed and transgenic tobacco with pCambia1304
Lane 1: Marker; ssRNA ladder (NEB).
Lane 2-3: Treated RNA of  non-transformed tobacco.
Lane 4-5: Treated RNA of transgenic tobacco with pCambia1304.
(b) Transgenic tobacco with  pToxo130BBI
Lane 1: Marker; ssRNA ladder (NEB).
Lane 2-17: Treated RNA of transgenic tobacco with  pToxo130BBI.
(c) Transgenic tobacco with pToxo130BBIKDEL
Lane 1: Marker; ssRNA ladder (NEB).
Lane 2-15: Treated RNA of transgenic tobacco with 
pToxo130BBIKDEL.
3000bp
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4.7.2 Reverse-transcriptase PCR on RNA of transgenic tobacco
The DNaseI treated RNA was used to synthesis cDNA using Reverse-
transcriptase PCR. The synthesized cDNA were prepared prior to Real-time PCR 
analysis. 
4.7.3 Real-time PCR using cDNA of transgenic tobacco
Three pairs of the primers (Actin9, gfp180 and TG13090) that designed for the 
relative quantification were examined with dissociation program for their specificity. 
The results are shown in Figure 4.32. From the dissociation curves, these three pair of 
primers showed only single peak, which indicated that they are qualified for Real-time 
PCR analysis.
Next, to ensure the equal amount of template is used, a standard curve was 
constructed based on relative quantification. The standard curve is prepared by 5 series 
of 5x serial dilution of cDNA. The amplification plot of three different primers sets 
(Actin9, gfp180 and TG13090) are shown in Figure 4.33. The generated average Ct 
values are summarized in Table 4.9 and graph of average Ct value versus Log cDNA 
input are shown in Figure 4.34. The linear equation and R square value of 3 pair primers 
were also included in the Figure 4.34. The values of R square are nearly 0.98 which 
indicated good confidence in correlating two values.
There are 3 samples of non-transformed (control), 3 samples of transgenic tobacco 
with pCambia1304 vector, 12 samples of transgenic tobacco with pToxo130BBI and 12 
samples of transgenic tobacco with pToxo130BBIKDEL have been studied in relative 
quantification. The amplification plots for 3 different sets primers with 4 different set 
samples are shown in Figure 4.35, 4.36 and 4.37.
The generated data from the relative quantification was analyzed with SDS 
Software 1.3.1. The results were summarized in Table 4.10 and bar charts (Figure 4.38 
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and 4.41). Based on bar chart in Figure 4.41, sample UT(3) is given negative result, it 
may due to contamination during preparation. Sample pToxo130BBIKDEL, 130BK(14) 
was not showed any result in both expression, as shown in Figure 4.38 and 4.39. It is 
likely due to the degradation of cDNA. The average mRNA level for the leaves 
transformed with the construct pToxo130BBI was 4.4 fold; while pToxo130BBIKDEL 
is 3.58 fold when compared to non-transformed. The mRNA level of pToxo130BBI was 
0.82-fold higher than pToxo130BBIKDEL.
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(a)
(b)
(c)
Figure 4.32: Dissociation curve of different primer sets at 60 ºC (Derivative versus 
temperature).
(a) Actin9 primers
(b) TG13090 primers
(c) gfp180 primers
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(b)
(c)
Figure 4.33: Amplification plot of 5x serial dilution cDNA (Delta Rn versus cycle).
(a) Actin9 primers
(b) TG13090 primers
(c) gfp180 primers
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Table 4.9: Average Ct value of 5 series of 5x serial dilution cDNA.
cDNA Input Log cDNA Input
Average Ct 
(Actin)
Average Ct 
(TG)
Average Ct 
(gfp)
1.0000 0 20.863 25.016 21.850
0.2000 -0.698970004 22.523 25.929 24.560
0.0400 -1.397940009 25.092 28.251 26.444
0.0080 -2.096910013 27.759 30.893 29.142
0.0016 -2.795880017 30.954 33.163 32.223
Figure 4.34: Graph of average Ct value of Actin, TG and gfp versus Log cDNA input.
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(a)
(b)
(c)
(d)
Figure 4.35: Amplification plot of cDNA using Actin9 primers (Delta Rn versus 
cycle).
(a) Non-transformed tobacco
(b) Transgenic tobacco with pCambia1304
(c) Transgenic tobacco with pToxo130BBI
(d) Transgenic tobacco with pToxo130BBIKDEL
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(b)
Figure 4.36: Amplification plot of cDNA using TG13090 primers (Delta Rn versus 
cycle).
(a) Transgenic tobacco with pToxo130BBI
(b) Transgenic tobacco with pToxo130BBIKDEL
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(a)
(b)
(c)
Figure 4.37: Amplification plot of cDNA of transgenic tobacco with pCambia1304 
vector by using gfp180 primers (Delta Rn versus cycle).
(a) Transgenic tobacco with pCambia1304
(b) Transgenic tobacco with pToxo130BBI
(c) Transgenic tobacco with pToxo130BBIKDEL
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Figure 4.38: Bar chart showing gene expression level of targeted gene (TG) of all 
samples.
Figure 4.39: Bar chart showing gene expression level of reporter gene (gfp) of all 
samples.
Detecto
Detecto
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Table 4.10: Summary of Real-time PCR analysis for gene expression in transgenic tobacco and non-transformed tobacco as control. The relative 
quantitation was obtained with standard curve method. The internal control of this analysis is beta-actin (Actin9) gene. UT(1) was used 
as the calibrator. CT, threshold cycle and RQ, relative quantitative.
Sample Average Ct of Actin9
Average Ct of 
TG
Average Ct of 
gfp
RQ Expression fold (Log RQ)
TG gfp TG gfp
UT(1) 22.131
(0.058)
Underestimated Underestimated - - - -
UT(2) 22.502(0.045) Underestimated Underestimated - - - -
UT(3) 20.746(0.139) Underestimated Underestimated - - - -
1304(1) 23.046(0.236) Underestimated
24.689
(0.086) - 946.385 - 2.976
1304(2) 22.767(0.183) Underestimated
22.913
(0.182) - 2672.489 - 3.427
1304(3) 21.626(0.069) Underestimated
20.651
(0.084) - 5811.036 - 3.764
130B(4) 21.105(0.150)
26.190
(0.050)
26.026
(0.023) 1280.154 97.626 3.107 1.990
130B(6) 23.093(0.064)
23.355
(0.080)
23.305
(0.074) 36215.426 2553.017 4.559 3.407
130B(7) 23.013(0.085)
26.469
(0.135)
26.121
(0.048) 3957.225 342.850 3.597 2.535
130B(8) 22.932(0.089)
22.084
(0.206)
21.771
(0.106) 78205.680 6613.540 4.893 3.820
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continued Table 4.10: Summary of Real-time PCR analysis for gene expression in transgenic tobacco and non-transformed tobacco as control. The 
relative quantitation was obtained with standard curve method. The internal control of this analysis is beta-actin (Actin9) gene. 
UT(1) was used as the calibrator. CT, threshold cycle and RQ, relative quantitative.
Sample Average Ct of Actin9
Average Ct of 
TG
Average Ct of 
gfp
RQ Expression fold (Log RQ)
TG gfp TG gfp
130B(10) 22.612
(0.107)
23.937
(0.090)
23.879
(0.184)
17330.643 1228.272 4.239 3.089
130B(11) 22.490(0.085)
23.903
(0.035)
24.208
(0.117) 16303.512 898.877 4.212 2.954
130B(12) 22.104(0.044)
24.588
(0.037)
24.538
(0.054) 7767.142 547.404 3.890 2.738
130B(13) 22.690(0.276)
24.615
(0.188)
24.389
(0.271) 11441.140 910.837 4.058 2.959
130B(15) 22.963(0.217)
20.546
(0.055)
20.030
(0.090) 231946.857 22586.496 5.365 4.354
130B(16) 22.353(0.116)
22.224
(0.102)
21.590
(0.088) 47514.098 5018.509 4.677 3.701
130B(17) 22.302(0.414)
20.378
(0.104)
19.572
(0.209) 164826.781 19612.881 5.217 4.293
130B(19) 22.295(0.093)
21.364
(0.093)
21.083
(0.099) 82828.469 6852.943 4.918 3.834
130BK(1) 23.242(0.113)
28.217
(0.060)
28.481
(0.025) 1381.332 78.311 3.140 1.894
130BK(2) 23.083(0.083)
28.460
(0.190)
28.422
(0.252) 1044.651 73.044 3.019 1.864
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continued Table 4.10: Summary of Real-time PCR analysis for gene expression in transgenic tobacco and non-transformed tobacco as control. The 
relative quantitation was obtained with standard curve method. The internal control of this analysis is beta-actin (Actin9) gene. 
UT(1) was used as the calibrator. CT, threshold cycle and RQ, relative quantitative.
Sample Average Ct of Actin9
Average Ct of 
TG
Average Ct of 
gfp
RQ Expression fold (Log RQ)
TG gfp TG gfp
130BK(3) 22.720
(0.109)
27.222
(0.028)
27.390
(0.146)
1917.380 116.123 3.283 2.065
130BK(4) 22.751(0.068)
27.521
(0.049)
27.472
(0.202) 1591.326 112.085 3.202 2.050
130BK(5) 23.598(0.099)
27.115
(0.027)
27.173
(0.036) 3794.330 248.275 3.579 2.395
130BK(6) 23.045(0.039)
27.329
(0.057)
27.810
(0.151) 2228.900 108.757 3.348 2.036
130BK(7) 22.259(0.095)
25.095
(0.019)
25.458
(0.056) 6080.688 321.871 3.784 2.508
130BK(9) 24.126(0.046)
22.585
(0.028)
23.358
(0.144) 126427.961 5035.770 5.102 3.702
130BK(13) 23.142(0.021)
28.229
(0.039)
28.114
(0.180) 1190.846 87.783 3.076 1.943
130BK(14) 22.625(0.142) Underestimated Underestimated - - - -
130BK(17) 22.331(0.023)
27.712
(0.110)
27.455
(0.083) 1042.062 84.816 3.018 1.928
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CHAPTER 5: DISCUSSION
5.1 Introduction
Toxoplasmosis is a parasitic disease caused by the one-celled protozoan parasite, 
Toxoplasma gondii, which is widespread in humans and many other warm-blooded 
animals in particular in cats and farm animals. This disease can cause serious effects in 
the infants, pregnant women and the unborn fetus. 
In this study, a recombinant scFv anti-Toxoplasma plant transformation construct 
was designed using a plant expression vector as a backbone and a pre-cloned mouse 
derived anti-Toxoplasma scFv gene (Lim, 2013) as the target. Single chain antibodies or 
scFvs are promising therapeutic molecules as they are not only similar to their parental 
antibodies but are smaller in size and with undemanding folding requirements 
facilitating their production in recombinant systems while still maintaining their 
functionality (Smith, 1996). As such the scFv gene has become attractive antibody 
derivative for various applications including as diagnostic and therapeutic candidates for 
human and animal applications. Up to now there are many therapeutic antibodies been 
studied and some were entered the clinical trials.  As reviewed by Lotter-Stark et al. 
(2012), there are four HIV neutralising antibodies (i.e. 2G12, b12, 2F5 and 4E10) have 
been successfully expressed in plants and the plant-made 2G12 has entered clinical 
trials in 2011 (Twyman et al., 2012). A plant expression system was chosen, as there 
have been several studies that have shown that the production of recombinant antibodies 
has high yield and lower cost when plants are used as biofactories (Sala et al., 2002; 
Fischer et al., 2004; Gao et al, 2012). Plants as biofactories can also minimise the 
potential risk of pathogenic contamination that is often associated with animal or 
bacterial cell culture systems. However, as in any production system, a major focus is in 
ensuring that the system will express at levels that will be amenable to practical use. A 
previous study in our laboratory utilising basic plant transformation constructs without 
96
KDEL or any other enhancing sequences showed low and unsatisfactory yields in 
producing scFv (Wong, 2011). Hence, the experiments also focused on adding elements 
to the construct that would ensure high expression levels in plant cells. Additionally the 
study initiated the use of the banana (Musa acuminata) plant as a future host for large 
scale production of antibodies in addition to the model host plant, Nicotiana tabacum. 
5.2 Development of constructs
The study successfully utilised standard molecular approaches to purify and 
subclone the gene of interests into the plasmids vector, pCambia1304, pToxo64BBI, 
pToxo64BBIKDEL, pToxo130BBI and pToxo130BBIKDEL. 
The BBIKDEL and BBI gene fragments
The Bowman-Birk Serine proteinase inhibitor (BBI) and KDEL retention 
sequences were used in this study as enhancements to the constructs which could 
potentially increase the expression levels of the targeted proteins in the plant cells.
It has been reported previously that transgenes that are targeted for expression 
within the endoplasmic reticulum showed improvement to the yield of protein 
(Benchabane et al., 2008). The KDEL retention sequence that was used in this study 
was Ser-Glu-Lys-Asp-Glu-Leu which was first described by Munro and Pelham (1987) 
that the presence of retention signal will retain the protein that secreted by transfected 
COS cells in endoplasmic reticulum only. With this unique characteristic, the retention 
signal was used in many other studies, as described by Galpin et al  in 2010. The human 
lysosomal enzyme, α-L-iduronidase (IDUA), with C-terminal ER-retention sequence 
was synthesized with lower concentrations of immunogenic sugars, i.e. fucose and 
xylose in seeds of transgenic Nicotiana tabacum and Brassica napus plants and thus 
increased the protein accumulation levels. Bellucci et. al (2007) also showed that the 
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production of recombinant zeolin was higher when targeted into the endoplasmic 
reticulum (ER) as compared to expression in the chloroplast of tobacco. Hence, this 
strategy was also used in this study to potentially facilitate better expression of the 
targeted antibody. 
A second approach for increasing the yield of recombinant protein production in 
plant cells is by addition of gene encoding protease inhibitors into the transgene 
constructs. Co-secretion of protease inhibitors with the transgene has the potential to 
protect recombinant protein from the host resident proteases activities. This was 
successfully demonstrated by Komarnytsky and his colleagues (2006) who showed that 
the production of immunoglobulin complexes in Nicotiana tabacum’s roots was higher 
with the co-secretion of Bowman-Birk Ser protease inhibitor. The Bowman-Birk Ser 
inhibitor used in this study was synthesised based on a sequence from gene bank 
(Accession number: EF127893) and originate from the genome of Musa acuminata
AAA group. The Bowman-birk inhibitor is well known with its unique function in 
defense against microorganisms, pathogen and insects predation (Koundal & Rajendran, 
2003; Yan et al., 2009; Dramé et al., 2013). This protease inhibitor is also involved in 
regulating the endogenous proteinases during germination and for formation of a 
sulphur reservoir during dormancy (Yan et al., 2009). 
5.3 Transformation of constructs into expression hosts
5.3.1 Agrobacterium-mediated transformation into banana cell suspensions
Musa acuminata was chosen as a potential host for expression and production of 
scFvs due to several attractive properties possessed by the plant. Principally, this is a 
tropical plant suitable to growing conditions in Malaysia with a physiology and large 
leaf architecture that potentially provides for large scale expression of proteins. The 
tissue culture and transformation protocols have also been well developed in our 
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laboratories (Wong et al., 2008). The banana cultivar used for the study cultivar 
Berangan is also amenable to large scale production via embryogenic cell suspensions 
process (Jalil et al., 2003).
In this study, transient assay utilizing GUS histochemical staining carried out on 
selected cells putatively transformed with Agrobacterium harbouring the scFv 
constructs developed showed initially promising results. The blue spots observed on the 
inoculated cell suspensions (as shown in Figure 4.21) suggested that the transformation 
of the constructs into the cell suspensions were successful. 
However, PCR analysis on the extracted DNA was negative indicating that the 
transgenes were not successfully integrated into plant genome. The positive results (blue 
colour spots) observed from the GUS assay was likely due to residual Agrobacterium sp.
located on the surface of cell suspensions. Difficulty in removing inoculum from 
putatively transformed primary cells is a recurring problem in transgenic experiments 
(Cubero et al., 2005; Dahdi et al., 2012) despite the use of antibiotics. The negative 
results of the experiments on the other hand could also be attributed to the state of the 
suspension cells used. The cells had been in culture for more than 24 months possibly 
rendering them less amenable to transformation (N. Khalid per comm). Banana cell 
suspensions have been successfully transformed in Musa acuminata cv, Mas (Wong, 
2007). However, there may also be differences in the efficiency of transformation in 
different banana cultivars. This possibility has not been reported and may be worth 
investigating. Future experiment would thus use fresh suspensions but no further work 
could be carried out for this study due to time constraints. It should be noted also that 
attempts to transform scFv in other monocots have shown low efficiency. Kamo et al. 
(2012) recently reported the expression of an scFv against Cucumber mosaic virus
(CMV) subgroup I and II in Gladiolus ‘peter Pears’ and ‘Jenny Lee’ where only 7% of 
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the transgenic plant lines were functional. The remaining work in this study focused on 
the use of tobacco as the expression host.
5.3.2 Agrobacterium-mediated transformation into tobacco
Agrobacterium-mediated transformation is a common tool for transforming 
foreign gene into tobacco. It is also the principle expression host that have been used for 
production of scFvs. Among the scFvs that have been produces in tobacco include the 
scFv anti-cucumber mosaic virus (Chua et al., 2006), scFv anti-foot-and-mouth disease 
(Joensuu et al., 2009) etc. Additionally, there are some scFvs undergoing the clinical 
tests, i.e. scFv for Melanoma that produce to target the P97 antigen was entered 
preclinical stage and the bispecific scFv for B-cell tumors was undergoing the Phase I 
clinical trials (Pucca et al., 2011).
The protocol that was used in this study was modified from the method of Fisher 
and Guiltinan in 1995. After transferring the gene of interest into tobacco leaf discs, the 
explants were regenerated in the antibiotic selection media.
The regenerated plantlets were selected and examined with GUS histochemical 
staining. The transgenic plantlets showed blue colour, while the non-transformed 
tobacco showed no colour changes after chlorophyll removal (as shown in Figure 4.25). 
As presented in the Figure 4.27, 4.28 and 4.29 showed that 17 out of 20 transgenic 
tobaccos harboured the transgene from pToxo130BBI; while 14 out of 20 were positive 
for transgene from pToxo130BBIKDEL. 
The transgenic tobaccos which showed expected results were further studied 
through RNA isolation and RT-qPCR for determination of the gene expression levels of 
the transgenes. The results of RT-qPCR as shown in Figure 4.38 and Figure 4.39, 
revealed that most of the samples of pToxo130BBI showed higher gene expression level 
of the targeted gene (Toxoplasmosis, TG) when compared to pToxo130BBIKDEL. The 
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same phenomenon was observed for the gene expression level of the reporter gene, 
green fluorescent protein (gfp) in the respective constructs. The results were unexpected 
as the dual element enhancer constructs (BBIKDEL) were expected to have higher 
expression than the single BBI construct. 
Theoretically, by the addition of the KDEL retention sequence to the scFv 
antibody gene is to direct and stabilize the foreign protein into the ideal environment for 
expression within the endoplasmic reticulum (ER), for higher protein accumulation 
(Schouten et al., 1996).  Additionally, co-expression with a protease inhibitor has been 
shown to be an effective tool for stabilizing and enhances the yield of the scFv antibody 
(Komarnytsky et al., 2006). However there have been no reports of both sequences 
being used in a single construct as attempted by this study. It should be noted that the 
results obtained from relative quantification studies are based on mRNA levels of the 
transgene in tobacco cells and not the protein accumulation level as reported by 
Schouten et al., 1996. 
Consequently, while the RT-qPCR results successfully showed the integration and 
functionality of the transgenes (pToxo130BBI and pToxo130BBIKDEL) to be 
expressed in tobacco, it did not provide quantitative evidence of protein accumulation. 
Further studies on the protein expression levels are needed to examine the real effect of 
additional KDEL retention sequence and co-expression with the Bowman-Birk Serine 
protease inhibitor.
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CHAPTER 6: CONCLUSION
This study was conducted to examine the transgene expression level of different 
constructs (pToxo64BBI, pToxo64BBIKDEL, pToxo130BBI and pToxo130BBIKDEL) 
in different plant expression system, banana cell suspension and tobacco. However, 
transformation into banana cell suspension was not successful and further optimization 
will have to carry out in future studies taking into account the observation from this 
study. Therefore, the remaining experiments were carried out using the tobacco system 
with two candidate constructs pToxo130BBI and pToxo130BBIKDEL.
Relative quantification studies of transgenic tobacco showed successful of 
transgene expression and transgene expression level and demonstrate the potential of 
system for production of anti-Toxoplasma scFv. However, there remains question the 
relationship between the transgene expression level and protein accumulation yield 
which merit further study and investigation. Additionally, further quantitative 
verification of the effect of KDEL retention sequence and Bowman-birk Serine protease 
inhibitor on protein expression levels need to be carried out.
The scFv transgenes (pToxo130BBI and pToxo130BBIKDEL) were successfully 
integrated into tobacco genome and have been expressed. However, further analysis is 
needed to examine the accumulation level and functionality of the scFv antibody. 
Western blot can be carried out for examining protein accumulation level; while, 
functionality of the anti-Toxoplasma scFv antibody can be studied using ELISA. 
Other than this, further studies such as large scale greenhouse trials for examining 
the stability of transgene in next generation and observation on the potential gene flow 
to other crops plants and other risk assessment parameters (Miki and McHugh, 2004) 
need to be included. The produced scFv antibody also needs to go through the clinical 
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trials.  Only with the successfully field trials and clinical trials, transgenic tobacco with 
this anti-Toxoplasma scFv antibody can be commercially produced.
However, biosafety issues of transgenic plants, especially for plant-produced 
pharmaceutical needs to be addressed especially in the context of the lack of specific 
regulations in Malaysia. Therefore, the risk assessment and risk management on this 
transgenic tobacco needs to be carried out thoroughly before any commercial release. 
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APPENDICES
Appendix A: Sterilization
All glassware, micropipette tips, microcentrifuge tubes, PCR tubes, stock 
solutions and buffers for DNA work were autoclaved at 121ºC with 15psi for 20 
minutes; while for RNA works, autoclaving cycle is at 121ºC  with15psi for 45 minutes.
The culture media for bacterial and plant tissues/cells were autoclaved at 121ºC 
with 15psi for 15minutes. The handling of plant tissue cultures were carried out in a 
laminar flow.
Appendix A1: Stock solutions, buffers and media of bacterial cultures
(i) LB broth
LB broth consists of 1.0g of Tryptone (1%), 0.5g of Sodium Chloride (0.17M), 
and 0.5g of Yeast Extract (0.5%), were dissolved in 80ml distilled H2O. Then, the 
volume was adjusted to 100ml and 10ml of the mixtures were aliquoted into 28ml 
universal bottle before sterilization.
(ii) LB agar plate
One gram of Tryptone (1%), 0.5g of Sodium Chloride (0.17M), 0.5g of Yeast 
Extract (0.5%), and 1.5g of agar were dissolved in 80ml distilled H2O. Then, the 
volume was topped up to 100ml and sterilized. For colony selection, the sterile mixtures 
were mixed with 100µg/µl kanamycin. Then, 25ml of the mixture were aliquoted into 
petri dish. After solidified, the plates were kept at 4ºC.
Appendix A2: Stock solutions, buffers and gel for electrophoresis
(i) 5x TBE buffer for DNA use
Tris base 54g 
Boric acid 27.5g 
0.5M EDTA (pH 8.0) 20ml 
Distilled H2O to 1000ml
Tris base, boric acid and EDTA were dissolved in distilled H2O and adjusted to the final 
volume of l000ml before sterilization. Then, the sterile solution was kept in room 
temperature. The solution was diluted to 1x working concentration (90mM Tris-borate 
and 2mM EDTA) for agarose gel electrophoresis. 
(ii) 5x TBE buffer for RNA use
The solution was prepared as mentioned above (Appendix A2, (i)) and treated 
with 1ml DEPC. The treated solution was incubated at room temperature for overnight 
before autoclaving. 
(iii) 6x DNA loading dye
1.0M Tris-Cl (pH7.6) 100µl 
bromophenol blue 30mg
xylene cyanol FF 30mg
0.5M EDTA 1.2ml
Glycerol 6ml
The compositions (as stated in Fermentas catalogue) were mixed well and adjusted to 
final volume of 10ml with sterile distilled H2O. The loading buffers were kept at room 
temperature.
(iii) 2x RNA loading dye
The loading dye was purchased from Fermentas with the composition of 95% 
formamide, 0.025% SDS, 0.025% bromophenol blue, 0.025% xylene cyanol FF, 0.025% 
ethidium bromide, and 0.5mM EDTA.  The loading dye was kept at -20ºC.
(iv) Molecular weight markers (Ladder)
The perfectTM 100bp DNA ladder and perfectTM 1kb DNA ladder were 
purchased from ERUX; while, ssRNA ladder was purchased from NEB. All the ladders 
were kept at -20ºC.
(v) Agarose gel
For preparing 1% agarose gel, 0.6g of the agarose were added into 60ml of 1x 
TBE buffer. Approximately 5µl of ethidium bromide were added into the gel.
Appendix A3: Stock solutions and buffer for plasmid extraction
(i) Alkaline Lysis Solution I
50mM glucose
25mM Tris-Cl (pH 8.0)
10mM EDTA (pH 8.0)
The solution was prepared from the standard stocks and sterilized by autoclaving. The 
solution was then kept at 4ºC.
(ii) Alkaline Lysis Solution II
0.2N NaOH
1% (w/v) SDS
The solution was prepared freshly from the stock solutions and used at room 
temperature.
(iii) Alkaline Lysis Solution III
5M potassium acetate 60ml
Glacial acetic acid 11.5ml
Sixty milliliter of 5M potassium acetate were added to 11.5ml glacial acetic acid. The 
mixture was adjusted to 100ml with sterile distilled H2O and stored at 4ºC.
(iv) 1M Tris-Cl (pH 8.0)
Tris base 12.11g
Distilled H2O to 100ml
Tris base was dissolved in 50ml of distilled H2O and pH was adjusted to 8.0 with 42ml 
concentrated HCl. Final adjustment to pH was carried out after the temperature of 
solution is cooled down to room temperature. The solution was adjusted to final volume 
of 100ml before sterilization. The solution was kept at room temperature.
(v) 0.5M EDTA (pH 8.0)
Disodium EDTA.2H2O 93.05g
Distilled H2O to 500ml
Disodium EDTA.2H2O was added in distilled H2O and stirred continuously while 
adjusting the pH. The pH is adjusted to 8.0 by using NaOH. (Note: The disodium salt of 
EDTA will only dissolve when the pH reached 8.0.) After pH adjustment, the solution 
was adjusted to final volume of 500ml and sterilized by autoclaving. 
(vi) 10N NaOH
NaOH 40g
Distilled H2O to 100ml
The NaOH pellets were dissolved in distilled H2O in a plastic beaker, as the preparation 
of 10N NaOH is highly exothermic reaction. The solution was stirred continuously until 
the pellet dissolved completely into distilled H2O. The solution was adjusted to final 
volume of 100ml and kept at room temperature.
(vii) 10% (w/v) SDS
Sodium dodecyl sulphate (SDS) 10g
Distilled H2O to 100ml
Sodium dodecyl sulphate was added into 80ml distilled H2O and stirred continuously 
until dissolve completely. The solution was adjusted to final volume of 100ml and kept 
at room temperature. 
(viii) 3M Sodium acetate (pH 5.2)
Sodium acetate (anhydrous) 40.83g
Distilled H2O to 100ml
Sodium acetate.3H2O was dissolved into 80ml and the pH was adjusted to 5.2 with 
glacial acetic acid. The solution was adjusted to final volume of 100ml before 
sterilization and kept at room temperature.
(ix) 70% (v/v) ethanol
Absolute ethanol 70ml
Sterile distilled H2O 30ml
Absolute ethanol was mixed well with the sterile distilled H2O before store at 4ºC.
Appendix A4: Stock solution and buffers of PCR
Appendix A4a: Stock solutions and buffers of conventional PCR
(i) PCR reaction mixture (11x)
The i-TaqTM DNA polymerase PCR kit was purchased from Intron 
Biotechnology. The compositions of the kit including 10x PCR buffer (with 20mM 
MgCl2), 10x MgCl2 free PCR buffer, 10mM dNTPs, 25mM MgCl2 and i-TaqTM DNA 
polymerase(5U/µl). The PCR reaction mixture was prepared as showed in Table A1.
Table A1: 11x PCR reaction mixture.
Component
Volume (µl) 
in 1x 
reaction
Volume (µl) in 
11x reaction
Final concentration 
in 1x reaction
10x PCR buffer (with 
20mM MgCl2)
5.00 55.00 1x
10mM dNTPs (2.5mM 
each) 4.00 44.00 0.2mM each
i-TaqTM DNA 
polymerase (5U/µl) 0.25 2.75 0.025U/µl
downstream primer 
(10µM) 5.00 55.00 1µM
upstream primer 
(10µM) 5.00 55.00 1µM
Template 4.00 44.00 1ng - 1µg
Sterile distilled H2O 26.75 294.25 -
Total 50 550 -
Appendix A4b: Stock solutions and buffers of Reverse-transcriptase PCR
(i) Reverse-transcriptase PCR reaction mixture (11x)
The High Capacity cDNA Reverse-transcription kit was purchased from Applied 
Biosystems. The kit consists of 10x RT buffer, 10x RT Random Primers, 25x dNTP mix 
(100mM), and MultiScribeTM Reverse-transcriptase (50U/µl). The reaction mixture was 
prepared as shown in Table A2.
Table A2: 11x Reverse-transcriptase PCR reaction mixture.
Component Volume (µl) in 1x reaction
Volume (µl) in 
11x reaction
Final concentration 
in 1x reaction
10x RT buffer 2.0 22.0 1x
25x dNTP mix (100mM) 0.8 8.8 1x (4mM)
10x RT Random Primers 2.0 22.0 1x
MultiScribeTM Reverse-
transcriptase (5U/µl) 1.0 11.0 0.25 U/µl
DEPC treated distilled H2O 4.2 46.2 -
Total 10 110 -
Appendix A4c: Stock solutions and buffers of Real-time PCR
(i) Real-time PCR reaction mixture (5x)
Power SYBR® Green PCR master mix (2x) was purchased from Applied 
Biosystems. The reaction mixture was prepared as shown in Table A3.
Table A3: 5x Real-time PCR reaction mixture.
Component Volume (µl) in 
1x reaction
Volume (µl) in 
5x reaction
Final concentration 
in 1x reaction
2x Power SYBR® Green 
PCR master mix 6.25 31.25 1x
Primer set mix (10µM) 1.25 6.25 1µM
cDNA template 1.0 5.0 -
DEPC treated distilled H2O 4.0 20.0 -
Total 12.5 62.5 -
Appendix A5: Restriction endonuclease and buffer for digestion
The restriction endonucleases and reaction buffers were purchased from NEB. 
Combinations of double restriction enzymes with buffer (optimum % activity) were 
showed in the following table, Table A4. 
Table A4: Combinations of double restriction enzymes with optimum buffer.
Table A5: Restriction enzyme, NdeI, with its optimum assay buffer.
Enzyme Enzyme Optimum assay buffer
Nco I Bgl II NEBuffer 3
Avr II Bgl II NEBuffer 2
Nco I Hind III NEBuffer 2
Avr II Hind III NEBuffer 2
Hind III Bgl II NEBuffer 2
Bam HI NcoI NEBuffer 3 + BSA
1x NEBuffer 2 contained:
NaCl 50 mM
Tris-HCl 10 mM
MgCl2 10 mM
DTT (dithiothreitol) 1 mM
1x NEBuffer 3 + BSA contained:
NaCl 100 mM
Tris-HCl 50 mM
MgCl2 10 mM
DTT (dithiothreitol) 1 mM
BSA 0.1mg/ml
1x NEBuffer 4 contained:
Potassium acetate 50 mM
Tris-acetate 20 mM
Magnesium Acetate 10 mM
DTT (dithiothreitol) 1 mM
Enzyme Optimum assay buffer
NdeI NEBuffer 4
Appendix A6: Ligase and buffers
T4 DNA Ligase (5U/µl) and assay buffer were purchased from Fermentas. 
Table A6: Reaction mixture of ligation.
Appendix A7: Stock solution and buffers for competent cell preparation
Appendix A7a: Stock solutions and buffers for E.coli strain JM109 competent 
cell preparation
(i) TFB I solution
RbCl2 1.2g 
MnCl2.4H2O 0.99g 
KoAc 0.3g 
CaCl2.4H2O 0.15g  
Glycerol 15ml
The chemicals were dissolved in 80ml sterile distilled H2O and pH is adjusted to 5.8 
with diluted acetic acid. Then, the solution was adjusted to final volume of 100ml and 
sterilized by filtration. The solution was then stored at 4ºC.
(ii) TFB II solution
RbCl2 0.12g 
MOPS 0.21g 
CaCl2.4H2O 1.10g  
Glycerol 15ml
Component Volume / Concentration of 1x reaction
Linear DNA vector 1:3 molar ration over insert
Insert DNA 3:1 molar ration over vector
10x T4 DNA Ligase buffer 2µl
T4 DNA Ligase (5U/µl ) 1U
Sterile distilled  H2O Adjust the final volume to 20µl
All chemical components were dissolved in 80ml sterile distilled H2O and stirred 
continuously. Then, the pH was adjusted to 6.8 with NaOH before adjusted to final 
volume of 100ml. The solution was sterilized by filtration and stored at 4ºC.
Appendix A7b: Stock solutions and buffers for Agrobacterium sp. strain 
LBA4404 competent cell preparation
(i) 1mM HEPES (pH7.0)
HEPES 23.83mg 
Sterile distilled H2O to 100ml
HEPES was dissolved in 80ml sterile distilled H2O and stirred continuously. Then, the 
pH was adjusted to 7.0 with NaOH before adjusted to final volume of 100ml. The
solution was sterilized by filtration and stored at 4ºC.
(ii) 10% (v/v) glycerol
Glycerol (100%) 10ml
Sterile distilled H2O 90ml
Glycerol was mixed well with sterile distilled H2O and filtered sterilization before store 
at 4ºC.
Appendix A8: Stock solutions, buffers and media for plant tissue cultures
Murashige and Skoog (MS) media powders contained macronutrients, 
micronutrients and vitamins were purchased from PhytoTechnology Laboratories®.
Appendix A8a: Stock solutions, buffers and media for banana cell suspensions
(i) M2 media
MS media powder 4.4g
2,4-D (lmg/ml) 1.1ml
Sucrose 20g
The chemical components were dissolved in 800ml distilled H2O and stirred 
continuously while adjusting the pH to 5.8 with 1N NaoH. The volume was adjusted to 
1000ml and sterilized by autoclaving. When the temperature of the media is cooled 
down to room temperature, 250µl of trans-zeatin (1mg/ml) were added. 
(ii) M2 media with 100µM Acetosyringone
The M2 media was prepared as stated as above (Appendix A8a ( i)), but in final 
volume 100ml. The media were stored at 4ºC. In the media, 100µl of 0.1M 
Acetosyringone were added before use.
(iii) M2 media with 50µg/l cefotaxime
The M2 media was prepared as stated in Appendix A8a (i). The media were stored 
at 4ºC. In the media, 50µl of 1mg/ml cefotaxime were added before use.
(iv) M3 media
MS media powder 4.4g
L-glutamine 0.4g
Sucrose 20g
The chemical components were dissolved in 800ml distilled H2O and stirred 
continuously. The pH was adjusted to 5.8 with 1N NaoH and the volume was adjusted 
to 1000ml before sterilized by autoclaving. The media were stored at 4ºC.
Appendix A8b: Stock solutions, buffers and media for tobacco tissue cultures
(i) MSO solid media
MS media powder 4.4g
Sucrose 30g
Phytagar 4g
The MS media powder and sucrose were dissolved in 800ml distilled H2O and stirred 
continuously. The pH was adjusted to 5.8 with 1N NaOH and the volume was adjusted 
to 1000ml. Then, 4g of phytagar were added before sterilized by autoclaving. The sterile 
media were aliquoted in sterile tissue culture jars and sealed with parafilm before stored 
at 4ºC.
(ii) Co-culture media
MS media powder 0.44g
Sucrose 3g
NAA (1mglml) 10µl
6-BA (1mg/ml) 100µl
The chemical components were dissolved in 80ml distilled H2O and stirred 
continuously. The pH was adjusted to 5.8 with 1N NaOH before adjusted the volume to 
100ml and sterilized by autoclaving. The sterile media were stored at 4ºC.
(iii) TSM media
MS media powder 4.4g
Sucrose 30g
NAA (1mglml) 100µl
6-BA (1mg/ml) 1000µl
Phytagar 4g
The chemical components were dissolved in 800ml distilled H2O and stirred 
continuously. The pH was adjusted to 5.8 with 1N NaOH before adjusted the volume to 
1000ml. Then, 4g of phytagar were added and sterilized by autoclaving. The sterile 
media were aliquoted in petri dishes and sealed with parafilm before stored at 4ºC.
(iv) TSM selection media
The media are prepared as stated in Appendix A8b (iii). Before aliquoted into 
petri dished, 250µl of 100mg/ml hygromycin and 2500µl of 100mg/ml cefotaxime were 
added and mixed well. The media were stored at 4ºC and need to be used within 2 
weeks.
(v) TRM selection media
The media are prepared as stated in Appendix A8b (iv) without 6-BA and 
aliquoted into sterile tissue culture jars before sealed with parafilm and stored at 4ºC. 
Appendix A9: Stock solutions and buffers for GUS histochemical staining reagent
(i) 0.2M NaPO4 buffer (pH 7.0)
0.2M NaH2PO4 (Solution A) 39ml
Na2HPO4 (Solution B) 61ml
Both solutions are prepared as mentioned in Appendix A9 (ii) and Appendix A9 (iii). 
After mixed well, the pH of buffer was adjusted to 7.0 with NaoH. The buffer was kept 
at 4ºC.
(ii) 0.2M NaH2PO4 (Solution A)
NaH2PO4 3.12g
Sterile distilled H2O to 100ml
Sodium phosphate was dissolved in 80m sterile distilled H2O before adjusted to final 
volume of 100ml. The solution was kept at 4ºC.
(iii) Na2HPO4 (Solution B)
Na2HPO4 2.84g
Sterile distilled H2O to 100ml
Disodium phosphate was dissolved in 80m sterile distilled H2O before adjusted to final 
volume of 100ml. The solution was kept at 4ºC.
(iv) 0.1M K3[Fe(CN)6]
K3[Fe(CN)6] 3.293g
Sterile distilled H2O to 100ml
Potassium ferricyanide was dissolved in 80ml sterile distilled H2O before adjusted to 
final volume of 100ml. The solution was kept at 4ºC.
(v) 0.1M K4[Fe(CN)6].3H2O
K4[Fe(CN)6].3H2O 3.293g
Sterile distilled H2O to 100ml
Potassium ferrocyanide was dissolved in 80ml sterile distilled H2O before adjusted to 
final volume of 100ml. The solution was kept at 4ºC.
(vi) 20M X-gluc
X-gluc 20mg
DMSO 1ml
X-gluc was dissolved in DMSO and stored at -20ºC before use. It is light sensitive.
(vii) 0.5% Triton X-100
Triton X-100 50µl
Sterile distilled H2O to 10ml
Triton-X-100 was mixed well sterile distilled H2O and keep at 4ºC.
(viii) GUS histochemical reagents mixture
Table A7: GUS histochemical reagents mixture for 10ml.
(ix) FAA solution
Absolute ethanol 45ml
Glacial acetic acid 5ml
Formaldehyde 5ml
Distilled H2O to 100ml
The chemicals were mixed well and adjusted to final volume of 100ml and stored at 4ºC.
Stock solutions
Working Solution
Concentration Volume, µl
0.2M NaPO4 buffer (pH 7.0) 0.1M 5000
0.1M K3[Fe(CN)6] 0.5mM 50
0.1M K4[Fe(CN)6].3H2O 0.5mM 50
0.5M EDTA (pH8.0) 10mM 200
20M X-gluc 1M 500
0.5% Triton X-100 0.1% 2000
Methanol 20% (v/v) 2000
Sterile distilled H2O - 200
Appendix A10: Agarose gel electrophoresis
(i) Agarose gel electrophoresis for DNA
Agarose gel was prepared as stated in Appendix A2 (vi) and transferred to a gel 
tank which contained 1x TBE buffer (diluted from 5x TBE).
The samples, each 5µl, were mixed with 1µl of 6x DNA loading dye on parafilm 
and loaded into the wells. After that, the samples were electrophoresed at 121volt for 
30minutes. 
The gel was visualized under ultraviolet light transilluminator of AlphaImagerTM
2200 and photograph was taken for result.
(ii) Agarose gel electrophoresis for RNA
The same protocol was used as stated in Appendix A10 (i) with the 5x TBE buffer 
of RNA used. However, there are some differences.
The RNA samples were mixed well with 2x RNA loading dye in equal volume in 
1.5ml microcentrifuge tubes. Then, the mixtures were heated at 70ºC for 10 minutes. 
After that, the heated mixtures were chilled on ice before loading into the gel.
The samples were electrophoresed at 120volt for 25 minutes. Then, the gel was 
visualized under ultraviolet light transilluminator of AlphaImagerTM 2200 and 
photograph was taken for result.
Appendix B: Compositions of Murashige and Skoog (MS)
Essential Element
Concentration in medium 
(mg/l)
Macroelement
Ammonium nitrate (NH4NO3)
Kalium nitrate (KNO3)
Calcium chloride (CaCl2.2H2O)
Magnesium sulphate (MgSO4.7H2O)
Potassium phosphate (KH2PO4)
1650
1900
440
370
170
Microelement
Potassium Iodide (KI)
Boric acid (H3BO3)
Manganase sulphate (MnSO4.4H2O)
Zinc sulphate (ZnSO4.7H2O)
Sodium manganate (Na2MnO4.2H2O)
Copper sulphate(CuSO4.5H2O)
Cobalt chloride(CoCl2.6H2O)
0.83
6.2
22.3
8.6
0.25
0.025
0.025
Iron source
Ferum sulphate (FeSO4.7H2O)
Ethylenediaminetetraacetic acid, disodium 
(Na2EDTA.2H2O)
27.8
37.3
Organic supplement
Myoinositol
Nicotinic acid
Pyridoxine-HCl
Thiamine-HCl
Glycine
100
0.5
0.5
0.5
2
Carbon source
Sucrose 30000
Sample Name:  scFv64_scFv64-F Signal Strengths:  A = 1913, C = 1928, G = 2289, T = 1884
Mobility:  KB_3730_POP7_BDTv3.mob Lane/Cap#:  15
Spacing:  14.0515 Matrix:  n/a
Comment:  n/a Direction:  Native
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Appendix C:   Sequence
Appendix C1:   Sequence of scFv64 antibody fragment
Sample Name:  scFv130_scFv130-F Signal Strengths:  A = 3958, C = 3986, G = 3588, T = 3705
Mobility:  KB_3730_POP7_BDTv3.mob Lane/Cap#:  9
Spacing:  13.9625 Matrix:  n/a
Comment:  n/a Direction:  Native
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Appendix C2:   Sequence of scFv130 antibody fragment
Sample Name:  090526Q7256-1(Y1209D)M13N- Signal Strengths:  A = 5177, C = 4532, G = 5662, T = 3896
Mobility:  KB_3730_POP7_BDTv3.mob Lane/Cap#:  69
Spacing:  15.5012 Matrix:  n/a
Comment:  n/a Direction:  Native
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350 360 370 380 390 400 410 420 430
T T G T A C CA G T G C A T G G A C C G G AT C C C C A A C T A C T G C C G G C G C CG G TG CA C G C C G G AG C C G C T C C T C G CG CA G T A G T A T T C G A G C C
440 450 460 470 480 490 500 510
A A T T A G A GG G T C C G G AG G T T T T GC C T T G T T C T GC T T G AG AT T T C C G T G G T G G T G T T G T T CC C A C C C T A T C G T C T C CA T T CA C C CA T
520 530 540 550 560 570 580 590 600
C A A T A G C G A T G T T A A T A G T G G A AG G C AT T C T C C C AA A A A AA A A A A A A A A A A A A A A A A A T C T G A GA A AG AT GA G C T C T A G A G AT C T
610 620 630 640 650 660 670 680
GA A T T CA C T G G C CG T C G T T T T A C AA CG T C G T G AC
690 700 710 720
Appendix C3:   Sequence of BBIKDEL gene fragment
Sample Name:  BBI(c5)_57BBI-R Signal Strengths:  A = 2565, C = 2409, G = 2461, T = 1556
Mobility:  KB_3730_POP7_BDTv3.mob Lane/Cap#:  2
Spacing:  13.084 Matrix:  n/a
Comment:  n/a Direction:  Native
GC G G AT TC T A T T AG G CA C C CAG G C T T T ACA C T T T A T G C T T C C G G C T CG T A T G T T G T G T G G A AT T G T G AG C G G A T
10 20 30 40 50 60 70
A A CA A T T T CA CA C A G G A A AC A G C T A T G AC C A T G A T T A C G C C A A G C T T T A CA A A C C C A A G G C A G AG C A G C C G AG AC T T G G C A A
80 90 100 110 120 130 140 150
A G A A AG A AG G A AG C G A A AG C G C G G A T AG A AG AC G C AG A T A T G A G G T AC A A C A T G G T G G T G T T CA G C C T G G T C C T C A T G G T G G C
160 170 180 190 200 210 220 230
G G C C G C C T T C T T CG C C T CCG C C AC C A C C A C CG C C T C C T C C T C CC A C C C G G AG C T C C G C T C T G C G C T G T C A A C C A A AG G G C AC G A
240 250 260 270 280 290 300 310 320
AG A AG A T G G AG A AG G A G T A G G AG AG AG G A GC AG G C AG A G G AG G AC A T G G C C G T G C T G CG A T CG G T G C G GC G G G T G C A C C A A A T C
330 340 350 360 370 380 390 400
C C A C C C CG C C G C AG T G C C AG T G C C AG G AC A T G G T G A G G T C G T G C C A C C C A T C G T G C CG G C A C T G C G T G CG C T CC C CG C T C A G C G
410 420 430 440 450 460 470 480 490
T G T CC C C G C CC T T G T A C C A G T G C A T G G A C C G G A T C CC C A A C T A C T G C C G G C G C CG G T G C A C G C C G G AG C C G C T C C T C G C G C A
500 510 520 530 540 550 560 570
G T A G T A T T C G A G C C A A T T A G AG G G T C C G G AG G T T T T G C C T T G T T C T G C T T G AG A T T T C C G T G G T G G T G T T G T T C C C A C C C T
580 590 600 610 620 630 640 650
A T C G T C T C C A T T C A C C C A T C AA T A G C G A T G T T AA T A G T G G A A G G C A T T C T C C C A A A A A A A A A A A A A A A A A A A A A A A T T T T T
660 670 680 690 700 710 720 730
GGA A AGA A AG A A C A A
740
Appendix C4:   Sequence of BBI gene fragment
Appendix D:   Poster Presentation
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INTRODUCTION
Toxoplasmosis is a parasitic disease caused by single celled
protozoa parasite, known as Toxoplasmosis gondii which is
widespread in human and many other warm-blooded animals,
especially, cats and farm animals. This disease causes serious
symptoms in infants, pregnant women and fetuses. There are
currently no effective vaccines for this disease. One potential
approach for treating the disease is the use of specific therapeutic
antibodies. In this study, an scFv gene coding for a recombinant
phage derived anti-Toxoplasma antibody will be introduced into a
plant expression system to produce the antibody in the plant cells
in large volume. The banana embryogenic cell suspensions were
used as plant biofactory in this study, because plantlet that
regenerate from somatic embryogenesis can prevent chimerism
formation.
OBJECTIVE
The aim of this study is to develop a recombinant antibody against 
Toxoplasmosis antigen which can be expressed in plant cells.
RESULTS AND DISCUSSION
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MATERIALS AND METHODS
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 221
EHA105 LBA4404
~1.5kb1kb
PCR Verification of the transgene in Agrobacterium by using specific 
primers.
Lane 1:        Marker; 1kb DNA Ladder.
Lane 2-20 : Different colonies of the Agrobacterium.
Lane21:      Plasmid of the construct as positive control.
Lane22:      Sterile distilled water as negative control.
Gus activity in banana embryogenic cell suspension 
after co-cultivation.
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~1.5kb
1kb
500bp
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Plasmid analysis of the construct after PCR screening.
Lane 1:      Marker; 1kb DNA Ladder.
Lane 2-7:  Plasmid of the construct after PCR selection.
PCR Verification of the construct  after extracted from 
E.coli by using specific primers.
Lane 1:       Marker; 100bp DNA Ladder.
Lane 2:       Sterile distilled water as negative control.
Lane 3-8:   Different plasmids were used as template.
In this study, the transgene was successfully introduced into the plant 
expression system. Therefore, further analysis being carried out on the 
regenerated plants to confirm the integration of transgene and also the 
level of expression.
Infection, 30 minutes, darkness
PCR Amplification by using self-designed primers
Cloning (E.coli JM109)
Colony  Selection
PCR Verification of the construct by using specific 
primers
Transformation into 
Agrobacterium
Co-cultivation, darkness, 4days
RegenerationGUS assay
Sequencing
RB KDELmgfp5 scFv bbi 35S 35S hpt LBgusA
Linear map of construct.
bbI : Bowman-birk Serine protease inhibitor
35S : 35S promoter of Cauliflower Mosaic Virus
hpt :  Hygromycin phosphotransferase
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INTRODUCTION
Toxoplasmosis is a parasitic disease caused by single celled
protozoa parasite, known as Toxoplasmosis gondii which is
widespread in human and many other warm-blooded animals,
especially, cats and farm animals. This disease causes
serious symptoms in infants, pregnant women and fetuses.
There are currently no effective vaccines for this disease.
One potential approach for treating the disease is the use of
specific therapeutic antibodies. In this study, an scFv gene
coding for a recombinant phage derived anti-Toxoplasma
antibody will be introduced into a plant expression system via
Agrobacterium sp. Plant was chosen as the platform to
produce the antibody because of its advantages, such as low
risk of human pathogenic contamination, the post-translation
modification and protein folding in plant system are similar to
human, and the antibody can be produced in large-scale.
OBJECTIVE
The aim of this study is to develop a recombinant antibody 
against Toxoplasmosis antigen which can be expressed in 
plant cells.
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MATERIALS AND METHODS
2 3 5 61 1 44 35 6 7 87 2
~1.5kb
1kb
500bp
1kb
In this study, the gene of interest is successfully integrated into the
plant genome. Further analysis need to carry out to study the
expression level and its stability in the next generation of the
pToxobbiKdel in the tobacco.
Antibiotic Selection
PCR Amplification by using self-designed primers
Cloning (E.coli JM109)
Colony  Selection
PCR Verification of the construct by using specific 
primers
Agrobacterium-mediated 
Transformation
Regeneration
DNA ExtractionGUS assay
DNA Sequencing
RB KDELmgfp5 scFv bbi 35S 35S hpt LBgusA
Figure 1: Linear map of construct, pToxobbiKdel.
gusA:    uid A gene encoding the β-glucuronidase
mgfp5:  green fluorescent protein
bbI :      Bowman-birk Serine protease inhibitor
35S :    35S promoter of Cauliflower Mosaic Virus
hpt :     Hygromycin phosphotransferase
PCR Analysis
Figure 4   PCR amplification using gfp
gene primers.
Lane 1-2: Untransformed tobacco; 
Lane3-10: Transgenic tobacco;
Lane11: Negative control, without DNA;
Lane 12: Positive control, using construct
plasmid as template; 
Lane 13: 100bp Marker.
Figure 3   PCR amplification using gfp
gene primers.
Lane 1: 100bp Marker;
Lane2-3: Untransformed tobacco;
Lane4-11: Transgenic tobacco;
Lane 12: Negative control, without DNA; 
Lane 13: Positive control, using construct 
plasmid as template.
Figure 2   GUS histochemical staining of the regenerated shoots.
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Transgenic tobaccos carrying pToxo130BBI and pToxo130BBIKDEL
were examined with real-time PCR to study the levels of expression of the
transgene. Surprisingly, the expression level of pToxo130BBI was 0.82-fold
higher compared to pToxo130BBIKDEL. This result is unexpected as
pToxo130BBIKDEL contained two elements for enhancing and stabilizing the
recombinant antibody, whilst pToxo130BBI only had one element. One
possibility for the lower expression level indicated in pToxo130BBIKDEL is
that the relative quantification studies carried out was based on mRNA level
of the transgene instead of protein accumulation levels in the transgenic
tobacco cells (Schouten, et al., 1996). The actual amount of successfully
accumulated protein may not be reflected by the level of transcript.
Furthermore, it is possible that the larger transgene cassette may also incur
a penalty to the amount of mRNA produced.
Thus, further studies on protein expression level such as by Western
Blot analysis needs to be carried out to examine the effectiveness of adding
the Bowman-birk Serine proteinase and KDEL retention sequence to the
recombinant protein.
ABSTRACT
Toxoplasmosis is a disease that widespread not only in humans, but
also in animals particularly farm animals. This disease is caused by a single-
celled protozoan parasite known as Toxoplasmosis gondii. Even though this
disease causes critical effect on human health and economic loses; however,
there are currently no effective vaccines on the market. A potential approach
in developing strategies to control the disease included the use of
recombinant antibodies targeting T.godii tachyzoites. As part of the
development of these antibodies in plant cells is also being explored. In this
study, the recombinant antibody was transformed into Nicotiana tabacum L.
cv. SR1 leaf disks through Agrobacterium-mediated transformation. The
recombinant antibody was co-expressed with a KDEL retention sequence
and Bowman-birk Serine proteinase inhibitor gene. PCR results showed the
successful transfer of the transgene integrated into the tobacco genome.
Further molecular analysis was carried out to examine the levels of
expression of transgene. As shown by the real-time PCR results, the average
mRNA levels for transgenic tobacco expressing pToxo130BBI (proteinase
inhibitor only) was 4.4-fold higher and only 3.58-fold higher for
pToxo130BBIKDEL (proteinase inhibitor plus KDEL) when compared to non-
transformed tobacco (control). The unexpected results are being verified by
analysis of the effectiveness of adding a KDEL retention sequence and
Bowman-birk Serine proteinase inhibitor genes individually in constructs and
through further quantitative analysis of the tobacco-expressed protein.
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Figure 1: Linear map of construct.
LB:        Left T-border
hpt :       Hygromycin phosphotransferase
CaMV35S: 35S promoter of Cauliflower Mosaic Virus
scFv130:     Recombinant antibody against Toxoplasmosis
bbI :      Bowman-birk Serine protease inhibitor
KDEL:    KDEL Retention Sequence
Mgfp5: Green Fluorescent protein
gusA:     β-Glucuronidase gene
RB:       Right T-border
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MATERIALS AND METHODS
RESULTS AND DISCUSSION
Figure 2.0:   GUS histochemical staining of the regenerated shoots.
Figure 3.0: PCR amplification using gfp gene primers. (a) Lane 1&12: 100bp Marker; Lane2-
11 & 13-22: Transgenic tobacco with pToxo130BBI; Lane 23: Negative control, without DNA;
Lane 24: Positive control, using construct plasmid as template; (b) Lane 1&14: 100bp Marker;
Lane2-11 & 15-24: Transgenic tobacco with pToxo130BBIKDEL; Lane 12: Negative control,
without DNA; Lane 13: Positive control, using construct plasmid as template.
Figure 4.0:   Gene expression level of recombinant antibody in tobacco.
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